A Comparison of Demographic, Epidemiological and Clinical Characteristics of Hospital Influenza-related Viral Pneumonia Patients

A Comparison of Demographic, Epidemiological and Clinical Characteristics of Hospital Influenza-related Viral Pneumonia Patients | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research article A Comparison of Demographic, Epidemiological and Clinical Characteristics of Hospital Influenza-related Viral Pneumonia Patients Bin Fu, Zhengjie Wu, Lingtong Huang, Zhaohui Chai, Peidong Zheng, and 5 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.2.24780/v2 This work is licensed under a CC BY 4.0 License Status: Under Review Version 2 posted 6 You are reading this latest preprint version Show more versions Abstract Objective: Through the comparison of the demographic, epidemiological, and clinical characteristics of hospital human influenza (influenza A (H1N1) pdm09, H3N2, and B) -related and hospitalized avian-origin influenza A (H7N9)-related viral pneumonia patients , find the different between them. Methods: A retrospective study was conducted in hospitalized influenza-related viral pneumonia patients. Results: Human influenza A -related patients in the 35–49-year-old group were more than those with B pneumonia patients (p=0.027), and relatively less in the ≥65-year-old group than B pneumonia patients (p=0.079). The proportion of comorbid condition to human influenza A pneumonia was lower than B pneumonia and H7N9 pneumonia patients (78% vs . 77.8%; p=0.013). The proportion of invasive mechanical ventilation (IMV), lymphocytopenia, elevated lactate dehydrogenase to hospitalized human influenza A-related viral pneumonia patients was higher than B pneumonia patients (p<0.05), but lower than H7N9 pneumonia patients (p<0.05). In the multivariate analysis, pulmonary consolidation (odds ratio (OR): 13.67; 95% confidence interval (CI): 1.54–121.12; p=0.019) and positive bacterial culture (sputum) (OR: 7.71; 95% CI: 2.48–24.03; p10,000/mm 3 (OR: 7.22; 95% CI: 1.47–35.58; p=0.015) and positive bacterial culture(blood or sputum) (OR: 6.27; 95% CI: 1.36–28.85; p=0.018) were independently associated with death in the three types hospitalized influenza-related viral pneumonia patients Conclusions: Hospital influenza B-related viral pneumonia mainly affects the elderly and people with underlying diseases, while human influenza A pneumonia mainly affects the young adults; however, the mortality was similar. The hospitalized human influenza A-related viral pneumonia patients was severer than B pneumonia patients,but milder than H7N9 pneumonia patients. Pulmonary consolidation and positive bacterial culture (sputum) were independently associated with IMV, while shock, white blood cell count >10,000/mm 3 , and positive bacterial culture (blood or sputum) were independently associated with death to three types hospitalized influenza-related viral pneumonia patients. Infectious Diseases human influenza A influenza B avian-origin influenza H7N9 viral pneumonia severe cases Background Influenza causes considerable morbidity during each annual influenza season. In April 2009, the influenza A (H1N1) pdm09 (pH1N1) virus emerged in Mexico and the USA and spread globally [1]. Since the first report of pneumonia that was caused by the pH1N1 virus in Mexico [2], severe cases have been documented worldwide. Influenza B virus has been classically considered less pathogenic than influenza A virus in adults and mostly responsible for mild respiratory infections, while severe illness and poor prognosis have been associated with bacterial coinfection [3,4]. On March 30, 2013, three individuals with severe pneumonia were found to be infected with a novel avian-origin influenza A (H7N9) virus that had not been detected in humans and animals previously. As of May 9, 2013, 131 laboratory-confirmed cases were reported, including 32 deaths [5], and the majority of these patients were reported in China. The comparison of the demographic, epidemiological, and clinical characteristics of hospital human influenza (influenza A (H1N1) pdm09, H3N2, and B) -related and hospitalized avian-origin influenza A (H7N9)-related viral pneumonia patients has not been reported.2017-2018 influenza season was dominated by pH1N1 and B viruses along with co-circulation of H3N2 virus, this season provided a unique opportunity to directly compare the demographic, epidemiological, and clinical characteristics of hospitalized human influenza A (pH1N1 and H3N2)-related viral pneumonia patients to the hospital influenza B-related viral pneumonia patients. Also, we compared the demographic, epidemiological, and clinical characteristics of these hospitalized human influenza (pH1N1, H3N2, and B)-related viral pneumonia patients to the hospital H7N9-related viral pneumonia patients in 2017, and aimed to discover the factors independently associated with invasive mechanical ventilation (IMV) or death among these three types hospitalized influenza-related viral pneumonia patients. Methods Study Design and Study Population A retrospective study was conducted from November 1, 2017 to March 31, 2018 at the First Affiliated Hospital, College of Medicine, Zhejiang University, China. All patients, >14 years of age and with hospital stay >24 h with confirmed human influenza A or B-related viral pneumonia were included in this study. In addition to above factors, those with confirmed H7N9-related viral pneumonia from January 1, 2017 to May 3, 2017 were also included. This study was approved by the Ethical Board of the hospital. This retrospective study evaluated the reverse transcriptase-polymerase chain reaction (RT-PCR) tests and computed tomography results daily in hospitalized patients with confirmed human influenza A- or B-related viral pneumonia or H7N9-related viral pneumonia. These cases were assessed by an Infectious Disease doctor and nasopharyngeal swabs (NPS) or sputum specimens were collected within the first 24 h of hospitalization and processed immediately. Influenza-related viral pneumonia was defined as confirmed human influenza A or B or H7N9 virus infection and the presence of a new infiltrate on computed tomography plus fever or respiratory symptoms. All radiological evaluations were performed by two radiologists who were blinded to the clinical information. Data Collection and Definitions Clinical data were acquired from electronic medical records. The following variables were recorded: demographics, comorbid conditions, current smoking status, alcohol abuse, pregnancy, body mass index (BMI), clinical feature, laboratory data, radiographic finding, complication, treatment, and clinical outcome. The definitions of obesity, current smoking status, alcohol abuse, confirmed human influenza A or B, confirmed H7N9, lymphocytopenia, thrombocytopenia, rhabdomyolysis, acute kidney injury, immunosuppression, early antiviral therapy, exposure to live poultry and severe cases were provided in the Supplementary Appendix. Statistical Analysis Categorical variables were compared by the chi-square or Fisher’s exact test. Continuous variables were compared by the t-test or the Mann–Whitney test. The multivariate logistic regression analysis of factors potentially associated with IMV or in-hospital mortality included the variables that were significant in the univariate analysis and clinically important variables. Statistical significance was established at p-value <0.05. All statistical analyses were performed using SPSS v.18. (SPSS Inc., Chicago, IL, USA). Results Demographic and Epidemiological Characteristics From November 1, 2017 to March 31, 2018, a total of 4,297 cases of laboratory-confirmed human influenza A and B viral infection were reported in our hospital. Of these, 2335 cases were human influenza A (about 85% were pH1N1 and 15% were H3N2), 1880 cases were influenza B, and 82 cases were infected with both viruses. Finally, 138 cases of hospitalized human influenza A-related viral pneumonia and 59 cases of hospitalized influenza B-related viral pneumonia were included in this study. From January 1 ,2017 to May 3 , 2017, a total of 18 cases of hospitalized H7N9 -related viral pneumonia were also included in the current study. The median age of hospitalized human influenza A-related viral pneumonia patients was lower than those with B pneumonia (57 years (interquartile range (IQR), 45.8–66.3) vs . 62 years (IQR, 53–74); p=0.034). In the 35–49-year-old age group, the proportion of hospitalized human influenza A-related viral pneumonia patients was 23.9%, which was higher than B pneumonia patients (10.2%; p=0.027). In the ≥65-year-old group, the proportion of hospitalized human influenza A-related viral pneumonia patients was 32.6%, which was relatively lower than B pneumonia patients (45.8%; p=0.079;Table 1). The proportion of comorbid conditions in hospitalized human influenza A-related viral pneumonia patients was 58%, which was lower than the B pneumonia patients and hospitalized H7N9 pneumonia patients (78% vs . 77.8%; p=0.013). Interestingly, 66.7% of hospitalized H7N9-related viral pneumonia patients were exposed to live poultry. Clinical Characteristics and Diagnostic Findings The most common symptoms of the three types of hospital influenza-related viral pneumonia patients were fever, cough, sputum production, shortness of breath, and fatigue(Table 2).. At the time of admission, the proportion of lymphocytopenia in hospitalized human influenza A-related viral pneumonia patients was 83.3%, higher than B pneumonia patients (69.5%; p=0.028). The proportion of elevated aspartate aminotransferase (AST), lactate dehydrogenase (LDH) in hospitalized human influenza A-related viral pneumonia patients was higher than that of B pneumonia patients (46.7% vs . 25.9%, p=0.007; 67.9% vs . 51%, p=0.033). The median value of lymphocyte count in hospitalized H7N9-related viral pneumonia patients was 425/mm 3 (IQR: 375 –625), lower than human influenza A and B pneumonia patients (745/mm 3 (IQR: 448–1208) vs . 1020/mm 3 (IQR: 550–1690); p=.001). The proportion of lymphocytopenia in hospitalized H7N9-related viral pneumonia patients was 100.0%, higher than human influenza A and B pneumonia patients (83.3% vs . 69.5%; p=0.006). The proportion of elevated AST, creatine kinase (CK), DD, and LDH in hospitalized H7N9-related viral pneumonia patients was higher than human influenza A and B pneumonia patients (77.8% vs . 46.7% vs . 25.9%, p<0.001; 76.5% vs . 17.9% vs . 9.8%, p<0.001; 94.4% vs . 76.5% vs . 62.5%, p=0.016; 100% vs . 67.9% vs . 51%, p=0.001). The proportion of positive culture (blood or sputum) on presentation or during hospitalization in the hospitalized H7N9-related viral pneumonia patients (bacterial) was 61.1%, higher than the human influenza A and B pneumonia patients (21.1% vs . 21.3%; p=0.002) Complications, Treatment, and Clinical Outcomes In the current study, the proportion of intensive care unit (ICU) admission in hospitalized human influenza A-related viral pneumonia patients was 19.6%, which higher than 6.8% of B pneumonia patients (p=0.024). The proportion of IMV in hospitalized human influenza A-related viral pneumonia patients was 16.7%, which also higher than that in B pneumonia patients 3.4% (p=0.01) (Table 3). The proportion of IMV in hospitalized H7N9-related viral pneumonia patients was 38.9%, which was higher than that in human influenza A and B pneumonia patients (16.7% vs . 3.4%; p=0.001). The median value of hospital expense of hospitalized H7N9-related viral pneumonia patients was 66095.6 Yuan (IQR, 42450.6–129574.2), which was higher than that of human influenza A and B pneumonia patients (IQR, 25642.3 Yuan (13184.5–53805.7) vs . 18316.8 Yuan (IQR, 11111.1–35750.5); p<0.001). There was no difference in death to three types of hospitalized influenza-related viral pneumonia patients. In the treatment, the rate of glucocorticoid use in hospitalized H7N9-related viral pneumonia patients was 100%, which was higher than human influenza A and B pneumonia patients (55.8% vs . 40.7%; p<0.001). All the hospitalized human influenza A-related viral pneumonia patients and hospitalized influenza B-related viral pneumonia patients were treated with aseltamivir or peramivir or both, and all the hospitalized H7N9-related viral pneumonia patients were treated with a combination of aseltamivir with peramivir. However, the time from onset of illness to administration of antiviral therapy in hospitalized H7N9-related viral pneumonia patients was 4 days (IQR, 3–8.3), which was relatively shorter than that of human influenza A and B pneumonia patients (7 days (IQR, 5–10.8) vs . 6 days (range, 3–14); p=0.089). The time of administration of antiviral therapy to virus-negative time of hospitalized H7N9-related viral pneumonia patients was 5.5 days (IQR, 2.8–10), shorter than human influenza A and B pneumonia patients (10 days (IQR, 6–14.5) vs . 11 days (IQR, 6–17.75); p=0.007). Factors associated with IMV due to Three Types Hospitalized Influenza-related Viral Pneumonia Patients In the univariate analysis, the three types hospitalized influenza-related viral pneumonia patients with IMV had significantly higher neutrophil percentage, C-reactive protein, AST, DD, blood urea nitrogen, pro-B-type natriuretic peptides, and partial pressure arterial oxygen/fraction of inspired oxygen (PaO 2 :FiO 2 ) levels than the three types hospitalized influenza-related viral pneumonia patients without IMV. Furthermore, the proportion of patients with shortness of breaths, lymphocytopenia, elevated procalcitonin, AST, CK, DD, and LDH, positive bacterial culture (sputum) on presentation or during hospitalization, positive bacterial culture (blood or sputum) on presentation or during hospitalization, CURB-65 score ≥2, bilateral pneumonia, and pulmonary consolidation in the three types of hospitalized influenza-related viral pneumonia patients with IMV was significantly higher than those without IMV, while the lymphocyte count in the three types of pneumonia patients with IMV was lower than those without IMV (Table S1 in the Supplementary Material). In the multivariate analysis, pulmonary consolidation (odds ratio (OR): 13.67; 95% confidence interval (CI): 1.54–121.12; p=0.019) and positive bacterial culture (sputum) at the time of presentation or during hospitalization (OR: 7.71; 95% CI: 2.48–24.03; p<0.001) were independently associated with IMV in the three types hospitalized influenza-related viral pneumonia patients(Table S3 in the Supplementary Material). Factors Associated with Death due to the three Types Hospitalized Influenza-related Viral Pneumonia Patients In the univariate analysis, the three types of hospitalized influenza-related viral pneumonia patients who die in the hospital had significantly higher neutrophil percentage, hemoglobin, blood platelet counts, C-reactive protein, DD, blood urea nitrogen, pro-B-type natriuretic peptides, and PaO 2 :FiO 2 levels than the survivors. Also, the proportion of elevated white blood cell count and procalcitonin, positive bacterial culture (sputum) on presentation or during hospitalization, CURB-65 score ≥2, IMV, shock to the three types hospitalized influenza-related viral pneumonia patients who die in the hospital was significantly higher than that of the survivors (Table S2 in the Supplementary Material). In the multivariate analysis, shock (OR: 13.16; 95% CI: 2.06–84.07; p=0.006), white blood cell count >10,000/mm 3 (OR: 7.22; 95% CI: 1.47–35.58; p=0.015) and positive bacterial culture(blood or sputum) on presentation or during hospitalization (OR: 6.27; 95% CI: 1.36–28.85; p=0.018) were independently associated with death in the three types hospitalized influenza-related viral pneumonia patients (Table 4). Discussion This was the first study that compared the demographic, epidemiological, and clinical characteristics of hospitalized human influenza-related viral pneumonia patients with H7N9 pneumonia patients. The study revealed that the hospitalized human influenza A-related viral pneumonia patients were younger than those with B pneumonia, and the infection was primarily detected in young adults. On the other hand, the influenza B-related viral pneumonia was common in the elderly, usually with comorbid conditions. Hospitalized human influenza A-related viral pneumonia patients was severer than B pneumonia patients,but milder than H7N9 pneumonia patients. The proportion of patients who have at least one comorbid condition in those with human influenza A-related viral pneumonia was lower than those with B pneumonia and H7N9 pneumonia patients. Moreover, the average age of hospitalized human influenza A-related viral pneumonia patients was lower than that of B pneumonia patients, and the proportion of the hospitalized human influenza A-related viral pneumonia patients in the 35–49 age group was more than that of the B pneumonia patients, and the proportion in the ≥65 years age group was relatively less than that of the B pneumonia patients. Some studies have reported that influenza B mainly affects the elderly and people with underlying diseases [6,7]; however, pH1N1 mainly affects young adults, similar to our research. Early-life exposure to an antigenically related virus, i.e., the A (H1N1) strain that circulated after the 1918 pandemic and prior to the 1957 A (H2N2) pandemic might mitigate the severity for the pH1N1 strain in older individuals; this phenomenon explained the survival of elderly in the pandemic.In china,the old people retire at 60 years of age and have more opportunities to shop in live-animal markets, therefore more likely to be exposed to the live-poultry, it can partially explain why the H7N9 patients have more comorbid conditions. In the aspect of clinical characteristics and diagnostic findings, CK was designated as a biomarker of severity in pH1N1 infection; the elevation of CK was associated with complications, increased length of ICU stay, and healthcare resources [8]. Another study included 155 hospitalized adult patients with pH1N1; LDH was an independent risk factor of hospital death as assessed by multivariate logistic regression analysis [9]. The elevation of DD may be caused by the embolism of the small pulmonary vessels, then the pulmonary ventilation and blood flow ratio became abnormal, and the blood oxygen saturation declined. Finally, the rate of mortality was elevated; however, this hypothesis needs further substantiation. A lymphocyte count of <300 lymphocytes/mL was observed in a subgroup of patients with poor outcome in a study encompassing 239 inpatients with confirmed influenza virus infection [10]. Thus, we can conclude that the proportion of elevated CK, LDH, DD, and lymphocytopenia was positively relative to the severity of influenza. In this study, the elevated LDHand lymphocytopenia in hospitalized human influenza A-related viral pneumonia patients was higher than that in B pneumonia patients, and the elevated CK, LDH, DD, and lymphocytopenia in hospitalized H7N9-related viral pneumonia patients was higher than that in human influenza A and B pneumonia patients. The proportion of ICU admission and invasive mechanical ventilation in hospitalized human influenza A-related viral pneumonia patients was higher than that in B pneumonia patients. The proportion of IMV and the median value of hospitalization expense in hospitalized H7N9-related viral pneumonia patients were higher than that in human influenza A and B pneumonia patients. Taken together, it can be concluded that the hospitalized human influenza A-related viral pneumonia patients was severer than B pneumonia patients,but milder than H7N9 pneumonia patients. A study consisting of 57 cases of H7N9 patients and 14 cases of pH1N1 patients demonstrated that the proportion of acute respiratory distress syndrome to H7N9 was much higher than that of pH1N1 [11], which was also observed in the current study. Furthermore, the proportion of ICU admission and IMV to pH1N1 was 2-fold higher than that of B, and no difference was detected in the mortality as reported by a study including 2791 cases of adult patients[12]. Another study reported that the mortality of adults influenza B patients was similar to that of pH1N1 patients [13]. Although all the influenza viruses infect the respiratory epithelium from the nasal passages to bronchioles, pH1N1 tends to infect pneumocytes and interalveolar macrophages, causing extensive areas of inflammation in the alveoli, which could partially explain the increased severity of pH1N1 [14-17]. Hospitalized influenza B-related viral pneumonia mainly affects the elderly and those with underlying diseases, rendering them as severe cases, such that the mortality of B pneumonia patients was elevated and similar to human influenza A pneumonia patients. Hypercytokinemia is characterized by the over-production of various proinflammatory cytokines and plays an significant role in disease severity and mortality in H5N1 patients [18]. Compared with pH1N1 infection, H7N9 virus infection tends to induce higher cytokine expression, resembling the cytokine storm observed in H5N1 infection[19]，which could partially explain why the H7N9 infection was severer than pH1N1. The World Health Organization Guidelines recommended that prompt empirical antiviral treatment should be initiated when influenza is suspected, even before laboratory results are known[20]. Improved clinical outcomes have been described among adults treated with antiviral drugs after hospitalization or up to 5 days from illness onset [21-23]. Early antiviral therapy within 2 days of illness accelerated viral shedding and reduced the mortality in patients with H7N9 viral infection [24]. Moreover, compared to early antiviral therapy, H7N9 patients with delayed antiviral therapy became severe cases [25]. Interestingly, in a study comprising of 82 cases of H7N9 virus infection, the time of onset of illness to administration of antiviral therapy was 6 days (IQR: 4–8), longer than that in the current study 4 days (IQR:3–8.3), and the administration of antiviral therapy to virus-negative time of the study was 7 days (IQR: 5– 9), also longer than 5.5 days (IQR: 2.8–10) in the current study; the mortality was 34.1% [26]. Gao et al. [27] reported that the rate of glucocorticoid use of the H7N9 cases was 62.2%, lower than our study 100% and the mortality was 27%. The mortality of hospitalized H7N9-related viral pneumonia patients was much higher than that of human influenza A and B pneumonia. However, in the current study, the mortality of hospitalized H7N9-related viral pneumonia patients was lower than before and similar to human influenza A and B pneumonia. This phenomenon might be explicated by the initial antiviral time relatively early than before and the rate of glucocorticoid use for H7N9 was high. All our patients received oseltamivir with peramivir that also may reduce the mortality, although these findings need to be substantiated further. In the current study, the proportion of early antiviral therapy in the three types of hospitalized influenza-related viral pneumonia patients was similar. Nevertheless, the present study has several limitations. First, influenza testing was ordered at the physicians’ discretion, and therefore, not all individuals with influenza were tested, or testing could be biased towards severe cases. However, this bias would not affect our main findings because influenza testing was ordered independently of the knowledge of the virus type or subtype. Second, we only included the hospitalized influenza-related viral pneumonia patients and excluded the outpatient cases and hospitalized patients without influenza-related viral pneumonia, such that it cannot reflect the whole disease spectrum. Finally, because the RT-PCR was not accurate absolutely, the real influenza-positive patients may be diagnosed as negative. Conclusion In summary, hospitalized influenza B-related viral pneumonia mainly affects the elderly and individuals with underlying diseases, while human influenza A pneumonia mainly affects the young adults; however, the mortality was comparative. The hospitalized human influenza A-related viral pneumonia patients was severer than B pneumonia patients,but milder than H7N9 pneumonia patients. Pulmonary consolidation and positive bacterial culture(sputum) at the time of presentation or during hospitalization were independently associated with IMV due to three types of hospital influenza-related viral pneumonia patients. On the other hand, shock, white blood cell count >10,000/mm 3 , and positive bacterial culture (blood or sputum) at the time of presentation or during hospitalization were associated with death in such patients. Abbreviations IMV: invasive mechanical ventilation; pH1N1: influenza A (H1N1) pdm09; H7N9: avian-origin influenza A(H7N9); RT-PCR: reverse transcriptase-polymerase chain reaction; NPS: nasopharyngeal swabs; BMI: body mass index; IQR: interquartile range; AST: aspartate aminotransferase; LDH: lactate dehydrogenase; DD: d-dimer ; CK: creatine kinase; ICU: intensive care unit; ECMO: extracorporeal membrane oxygenation; PaO2:FiO2: partial pressure arterial oxygen/fraction of inspired oxygen; OR: odds ratio; CI: confidence interval; SCr: serum creatinine Declarations Acknowledgments We acknowledge the contributions of other clinical and technical staff of the First Affiliated Hospital, College of Medicine, Zhejiang University. Funding This work was supported by grants from the Natural Science Foundation of China (No. 81872672) and National Science and Technology Major Project (No. 2017ZX10204401). Availability of data and materials All data generated or analysed during this study are either included in this published article and its supplementary information files or are available from the corresponding author on reasonable request. Authors’ contributions Study concept and design: Bin Fu and Lingling Tang. Acquisition of data: Bin Fu, Zhengjie Wu, Lingtong Huang, Zhaohui Chai, and Peidong Zheng. Analysis and interpretation of data: Bin Fu ,Zhengjie Wu, and Lingling Tang. Drafting of the manuscript: All authors. Critical revision of the manuscript for intellectual content: All authors. All authors agree with the submission. Authors details 1 State Key Laboratory for Diagnosis and Treatment of Infectious Disease, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Centre for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou310003, P.R.China. 2 Department of Critical Care Medicine, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou310003, P.R.China. 3 Department of Neurosurgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou310003, P.R.China. 4 Department of Dermatology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou310003, P.R.China. 5 Department of Nosocomial infection，The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou310003, P.R.China. 6 Department of Infectious Diseases, the Hangzhou Hosipital of Traditional Chinese Medicine. 7 Shulan(Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College,Hangzhou310006, P.R.China. Competing interests The authors declare that they have no competing interests. Consent for publication Not applicable. Ethics approval and consent to participate The local ethics committee (The First Affiliated Hospital, College of Medicine, Zhejiang University) approved this study. References Brammer L, Blanton L, Epperson S, et al. Surveillance for influenza during the 2009 influenza A (H1N1) pandemic-United States, April 2009–March 2010. Clin Infect Dis 2011; 52:S27–35. Perez-Padilla R , de la Rosa-Zamboni D , Ponce de Leon S , et al ; INER Working Group on Influenza . Pneumonia and respiratory failure from swine-origin infl uenza A (H1N1) in Mexico . N Engl J Med. 2009 ; 361 ( 7 ): 680 - 689 . Aebi T, Weisser M, Bucher E, Hirsch HH, Marsch S, Siegemund M. Co-infection of influenza B and Streptococci causing severe pneumonia and septic shock in healthy women. BMC Infect Dis 2010;10:308 (1471-2334 (Linking)). Kim YH, Kim HS, Cho SH, Seo SH. Influenza B virus causes milder pathogenesis and weaker inflammatory responses in ferrets than influenza A virus. Viral Immunol 2009;22(6):423e30. Number of confirmed human cases of avian influenza A(H7N9) reported to WHO. Geneva: World Health Organization, May 2013 ( http://www.who.int/ influenza/human_animal_interface/influenza_h7n9/05_ReportWebH7N9Number.pdf). Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, et al. Influenza-associated hospitalizations in the United States. JAMA 2004;292(11):1333e40. Treanor JJ. Virus de la gripe. In: In: Mandell GL, Bennett JE, Dolin R, editors. Enfermedades infecciosas: principios y practica . 6th ed., vol. 2. Madrid: Elsevier INC; 2005. p. 2060e85. Ba´rbara Borgatta，Marcos Pe ´rez，Loreto Vidaur, et al. Elevation of creatine kinase is associated with worse outcomes in 2009 pH1N1 influenza A infection. Intensive Care Med (2012) 38:1152–1161. Xiuming Xi, Yuan Xu, Li Jiang , et al. Hospitalized adult patients with 2009 influenza A(H1N1) in Beijing, China: risk factors for hospital mortality. BMC Infectious Diseases 2010, 10:256. Antonio Lalueza, Dolores Folgueira, Carmen Díaz-Pedroche, et al. Severe lymphopenia in hospitalized patients with influenza virus infection as a marker of a poor outcome, Infectious Diseases. 2019; VOL. 51,NO. 7, 543–546. 11. Wenrui Wu, Ding Shi, Daiqiong Fang, et al. A new perspective on C-reactive protein in H7N9 infections. International Journal of Infectious Diseases 44 (2016) 31–36. Sandra S. Chaves, Deborah Aragon, Nancy Bennett, et al. Patients Hospitalized With LaboratoryConfirmed Influenza During the 2010–2011 Influenza Season: Exploring Disease Severity by Virus Type and Subtype. The Journal of Infectious Diseases 2013;208:1305–14. A. Gutie´rrez-Pizarraya, P. Pe´rez-Romero, R. Alvarez,et al. Unexpected severity of cases of influenza B infection in patients that required hospitalization during the first postpandemic wave. Journal of Infection (2012) 65, 423e430. Huang SS, Banner D, Fang Y, et al. Comparative analyses of pandemic H1N1 and seasonal H1N1, H3N2, and influenza B infections depict distinct clinical pictures in ferrets. PLoS One 2011; 6:e27512. Guarner J, Falcón-Escobedo R. Comparison of the pathology caused by H1N1, H5N1, and H3N2 influenza viruses. Arch Med Res 2009; 40: 655–61. Itoh Y, Shinya K, Kiso M, et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 2009; 460: 1021–5. Munster VJ, de Wit E, van den Brand JM, et al. Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in ferrets. Science 2009; 325:481–3. Zhou J, Wang D, Gao R, Zhao B, Song J, Qi X, et al. Biological features of novel avian influenza A (H7N9) virus. Nature 2013;499:500–3 de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, Chau TN, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load andhypercytokinemia. Nat Med 2006;12:1203–7 Centers for Disease Control and Prevention. Antiviral agents for the treatment and chemoprophylaxis of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2011; 60:1–24. Lee N, Choi KW, Chan PK, et al. Outcomes of adults hospitalised with severe influenza. Thorax 2010; 65:510–5. McGeer A, Green KA, Plevneshi A, et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 2007; 45:1568–75. Louie JK, Yang S, Acosta M, et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. Clin Infect Dis 2012; 55:1198–204. Shufa Zheng, Lingling Tang, Hainv Gao, et al. Benefit of Early Initiation of Neuraminidase Inhibitor Treatment to Hospitalized Patients With Avian Influenza A(H7N9) Virus. Clinical Infectious Diseases 2018;66(7):1054–60. Leung YH, To MK, Lam TS, Yau SW, Leung OS, Chuang SK. Epidemiology of human influenza A(H7N9) infection in Hong Kong. J Microbiol Immunol Infect. 2015;S1684-1182(15)00772-0. Yan Zhang, Hainv Gao, Weifeng Liang, et al.Efficacy of oseltamivir-peramivir combination therapy compared to oseltamivir monotherapy for Influenza A (H7N9) infection: a retrospective study. BMC Infectious Diseases (2016) 16:76. 27. Hai-Nv Gao, Hong-Zhou Lu, Bin Cao,et al. Clinical Findings in 111 Cases of Influenza A (H7N9) Virus Infection. N Engl J Med 2013;368:2277-85. Tables Table 1 Comparison of Demographic and Epidemiological Characteristics of three types Hospitalized Influenza-related Viral Pneumonia Patients Characteristics B ( n =59 ) A ( n =138 ) H7N9 ( n =18 ) p -value among (a) (b) (c) (a) and (b) (a), (b), and (c) Demographic data Age (y) median (IQR) 62 (53 – 74) 57 (45.8 – 66.3) 60 (43.3 – 68) 0.034 0.095 Age subgroup (y), no. (%) 14 – 34 7 (11.9) 12 (8.7) 1 (5.6) 0.490 0.752 35 – 49 6 (10.2) 33 (23.9) 4 (22.2) 0.027 0.080 50 – 64 19 (32.2) 48 (34.8) 7 (38.9) 0.726 0.863 ≥ 65 27 (45.8) 45 (32.6) 6 (33.3) 0.079 0.205 Female, no. (%) 22 (37.3) 49 (35.5) 4 (22.2) 0.812 0.486 Comorbid conditions, no. (%) Any one condition 46 (78.0) 80 (58.0) 14 (77.8) 0.007 0.013 Chronic pulmonary disease 7 (11.9) 20 (14.5) 2 (11.1) 0.623 0.949 Diabetes 5 (8.5) 24 (17.4) 2 (11.1) 0.106 0.289 Hypertension 21 (35.6) 54 (39.1) 8 (44.4) 0.640 0.778 Chronic renal diseases 5(8.5) 7 (5.1) 2 (11.1) 0.556 0.327 Chronic liver diseases 7 (11.9) 15 (10.9) 5 (27.8) 0.839 0.132 Chronic cardiovascular disease 5 (8.5) 25 (18.1) 2 (11.1) 0.085 0.224 Chronic neurological disease 4 (6.8) 5 (3.6) 1(5.6) 0.549 0.495 Hematological diseases 10 (16.9) 12 (8.7) 0 (0) 0.092 0.085 Immunosuppression 7 (11.9) 11 (8) 0 (0) 0.385 0.305 Pregnancy 0 (0) 1 (0.7) 0 (0) 1.000 1.000 Current smoker 9 (15.3) 36 (26.1) 7 (38.9) 0.097 0.076 Alcohol abuse 8 (13.6) 27 (19.6) 3 (16.7) 0.312 0.633 BMI, no. (%) obesity+morbid obesity 0 (0) 7 (5.1) 0 (0) 0.105 0.229 Exposure to live poultry in previous 14 days, no. (%) NA NA 12 (66.7) Abbreviations: IQR interquartile range *Overall missing data for different categories varied Body mass index: For human influenza A, there were 40 miss dates; for B, there were 18 miss dates; for H7N9, there were 3 miss dates Table 2 Comparison of Clinical Characteristics of Three Types Hospitalized Influenza-related Viral Pneumonia Patients Characteristics B ( n =59 ) A ( n =138 ) H7N9 ( n =18 ) p -value among (a) (b) (c) (a) and (b) (a), (b), and (c) Clinical features Fever Any no. (%) 54 (91.5) 123 (89.1) 17 (94.4) 0.620 0.819 Maximal temperature subgroup, no (%) 37.3 – 38.0 °C 11 (20.4) 12 (10.6) 3 (18.8) 0.046 0.173 38.1 – 39.0 °C 25 (46.3) 46 (40.7) 6 (37.5) 0.226 0.734 >39.0 °C 18 (33.3) 55 (48.7) 7 (43.8) 0.213 0.174 Cough 52 (88.1) 120 (87) 17 (94.4) 0.820 0.845 Sputum production 50 (84.7) 106 (76.8) 16 (88.9) 0.209 0.348 Shortness of breath 29 (49.2) 83 (60.1) 12 (66.7) 0.154 0.260 Fatigue/weakness 34 (57.6) 67 (48.6) 6 (33.3) 0.243 0.175 Myalgia 4 (6.8) 16 (11.6) 1 (5.6) 0.305 0.617 Laboratory findings White blood cells count/mm 3 , median (IQR) 6900 (4300 – 12600) 7000 (4300 – 9550) 4400 (3475 – 5625) 0.407 0.008 Subgroup, no. (%) >10,000/mm 3 17 (28.8) 32 (23.2) 1 (5.6) 0.403 0.120 <4000/mm 3 13 (22) 28 (20.3) 7 （ 38.9 ） 0.782 0.224 Lymphocytes count/mm 3 , median (IQR) 1020(550-1690) 745(448 – 1208) 425(375 – 625) 0.340 0.001 Lymphocytopenia, no. (%) 41 (69.5) 115 (83.3) 18 (100) 0.028 0.006 Hemoglobulin — g/dl, median (IQR) 117 (95 – 130) 124 (104 – 139) 117 (109.3 – 129) 0.018 0.058 Platelets count/mm 3 , median (IQR) 159000 (107000 – 251000) 164500 (103300 – 250000) 139000 (93800 – 173500) 0.842 0.335 Thrombocytopenia, no. (%) 26 (44.1) 60 (43.5) 11 (61.1) 0.939 0.361 C-reactive protein >10 mg/L, no. (%) 46 (82.1) 115 (83.9) 16 (88.9) 0.760 0.836 Procalcitonin >0.5 ng/mL, no. (%) 8 (25.8) 34 (31.8) 8 (44.4) 0.525 0.401 Alanine aminotransferase >40 U/L, no. (%) 15 (25.9) 50 (36.5) 8 (44.4) 0.150 0.229 Aspartate aminotransferase >40 U/L, no. (%) 15 (25.9) 64 (46.7) 14 (77.8) 0.007 21 μmol/L, no. (%) 5 (8.6) 10 (7.3) 0 (0) 0.982 0.585 Creatinine >104 μmol/L (1.5 mg/dL), no. (%) 12 (20.3) 19 (13.9) 2 (18) 0.255 0.479 Lactate dehydrogenase >250 U/L, no. (%) 26 (51) 91 (67.9) 17 (100) 0.033 0.001 Creatine kinase >200 U/L, no. (%) 5 (9.8) 24 (17.9) 13 (76.5) 0.175 <0.001 PaO 2 :FiO 2 (mmHg), median (IQR) 227.5 (173.5 – 302.8) 214.1 (136.6 – 293.2) 171.6 (137.5 – 233.3) 0.214 0.118 PaO 2 :FiO 2 ≤ 300 mmHg, no. (%) 23 (71.9) 75 (78.1) 16 (88.9) 0.470 0.410 D-dimer >700 m g/L, no. (%) 35 (62.5) 104 (76.5) 17 (94.4) 0.049 0.016 Positive culture (blood or sputum) on presentation or during hospitalization, no. (%) Bacterial 10 (21.3) 24 (21.1) 11 (61.1) 0.975 0.002 Fungal 3 (6.4) 18 (15.8) 6 (33.3) 0.107 0.028 Radiographic findings Computed tomography consistent with pneumonia at admission, no. (%) Involvement of both lungs 52 (88.1) 121 (87.7) 16 (88.9) 0.929 1.000 Ground-glass opacity 12 (20.3) 49 (35.5) 10 (55.6) 0.035 0.012 Consolidation 29 (49.2) 88 (63.8) 18 (100) 0.056 <0.001 CURB -65 score ≥ 2 18 (30.5) 38 (27.5) 6 (33.3) 0.672 0.798 Abbreviations: PaO 2 :FiO 2 , partial pressure arterial oxygen/fraction of inspired oxygen; IQR, interquartile range. *Overall missing data for different categories varied Maximal temperature: For human influenza A, there were 25 miss dates; for B, there were 5 miss dates; for H7N9, there were 2 miss dates C-reactive protein: For human influenza A, there were 2 miss dates; for B, there were 2 miss dates Procalcitonin: For human influenza A, there were 32 miss dates; for B, there were 28 miss dates Alanine aminotransferase ： For human influenza A, there were 2 miss dates; for B, there was 1 miss date Aspartate aminotransferase: For human influenza A, there were 2 miss dates; for B, there was 1 miss date Total bilirubin: For human influenza A, there were 2 miss dates; for B, there was 1 miss date Creatinine: For human influenza A, there were 2 miss dates Lactate dehydrogenase: For human influenza A, there were 5 miss dates; for B, there were 8 miss dates; for H7N9, there were 2 miss dates Creatine kinase: For human influenza A, there were 5 miss dates; for B, there were 8 miss dates; for H7N9, there were 2 miss dates Partial pressure arterial oxygen/fraction of inspired oxygen: For human influenza A, there were 43 miss dates; for B, there were 27 miss dates D-Dimer: For human influenza A, there were 3 miss dates; for B, there were 3 miss dates Positive culture (blood or sputum) on presentation or during hospitalization(bacterial): For human influenza A, there were 25 miss dates; for B, there were 12 miss dates Positive culture (blood or sputum) on presentation or during hospitalization(fungal): For human influenza A, there were 25 miss dates; for B, there were 12 miss dates Table 3 Comparison of Complications, Treatment, and Clinical Outcomes of Three Types Hospitalized Influenza-related Viral Pneumonia Patients Characteristics B ( n =59 ) A ( n =138 ) H7N9 ( n =18 ) p -value among (a) (b) (c) (a) and (b) (a), (b), and (c) Complications 7 (12) 16 (12) 4 (22.2) 0.957 0.411 Shock 1 (1.7) 9 (6.5) 1 (5.6) 0.289 0.315 Acute kidney injury 5 (8.5) 11 (8) 2 (11.1) 1.000 0.793 Rhabdomyolysis 1 (1.7) 1 (0.7) 1 (5.6) 0.510 0.147 Treatment Oxygen therapy, no. (%) 44 (74.6) 101 (73.2) 18 (100) 0.840 0.022 Antiviral treatment, no. (%) 52 (88) 152 (93) 18 (100) 0.720 0.388 Oseltamivir 36 (69.2) 70 (56.5) 0 (0) 0.114 <0.001 Peramivir 9 (17.3) 32 (25.8) 0 (0) 0.224 0.020 Both 7 (13.5) 22 (17.7) 18 (100) 0.485 <0.001 Timing from onset of illness to administration of antiviral therapy, median (IQR) 6 (3 – 14) 7 (5 – 10.8) 4 (3 – 8.3) 0.797 0.089 0–2 days 9 (17.6) 14 (11.3) 1 (18) 0.258 0.384 3–5 days 12 (23.5) 31 (25) 57 (34.8) 0.837 0.091 ≥6 days 30 (58.8) 79 (63.7) 8 (44.4) 0.544 0.281 Timing from administration of antiviral therapy to virus negative, median (IQR) 11 (6 – 17.75) 10 (6 – 14.5) 5 (2.8 – 10) 0.260 0.007 Admission to ICU, no. (%) 4 (6.8) 27 (19.6) 15 (83.3) 0.024 0.054 Mechanical ventilation Noninvasive 6 (10.2) 14 (10.1) 0 (0) 0.996 0.528 Invasive 2 (3.4) 23 (16.7) 7 (38.9) 0.001 0.001 Extracorporeal membrane oxygenation 0 (0) 2 (1.4) 2 (11.1) 1.000 0.048 Blood purification 4 (6.8) 3 (2.2) 2 (11.1) 0.200 0.072 Antibiotics 56 (94.9) 134 (97.1) 17 (94.4) 0.430 0.416 Antifungal 22 (37.3) 42 (30.4) 13 (72.2) 0.347 0.002 Glucocorticoids 24 (41) 77 (56) 18 (100) 0.052 <0.001 Clinical outcome Death 5 (8.5) 13 (9.4) 0 (0) 0.833 0.542 Total hospitalization expenses (Yuan), median (IQR) 18316.8 (11111.1 – 35750.5) 25642.3 (13184.5 – 53805.7) 66095.6 (42450.6 – 129574.2) 0.094 <0.001 Abbreviations: ICU, intensive care unit; IQR, interquartile range . *Overall missing data for different categories varied Timing from onset of illness to administration of antiviral therapy: For human influenza A, there were 14 miss dates; for B, there were 8 miss dates Timing from administration of antiviral therapy to virus negative: For human influenza A, there were 73 miss dates; for B, there were 39 miss dates Total hospitalization expenses: For human influenza A, there were 14 miss dates; for B, there were 6 miss dates Table 4 Multivariate Analysis of Factors Associated with Death due to Three Types Hospitalized Influenza-related Viral Pneumonia Patients Variables OR (95% CI) p-value White blood cell count >10,000/mm 3 7.22 (1.47–35.58) 0.015 Hemoglobulin (g/dL) 0.100 Platelets count/mm 3 0.851 C-reactive protein (mg/L) 0.772 Procalcitonin >0.5 ng/mL 0.621 D-dimer >2100 m g/L 0.387 Pro-B-type natriuretic peptides (pg/mL) 0.231 Positive bacterial culture (blood or sputum) 6.27 (1.36 – 28.85) 0.018 on presentation or during hospitalization Computed tomography consistent with 0.427 pulmonary consolidation at admission Shock* 13.16 (2.06 – 84.07) 0.006 * Shock Shock at any point during the illness Abbreviations: OR odds ratio ， CI confidence interval *Overall missing data for different categories varied Pro-B-type natriuretic peptides: For human influenza A, there were 62 miss dates; for B, there were 42 miss dates; for H7N9, there were 11 miss dates Supplementary Files SupplementaryMaterial.doc Cite Share Download PDF Status: Under Review Version 2 posted Reviewer # 1 agreed at journal 10 Apr, 2021 Review # 1 received at journal 10 Apr, 2021 Reviewers invited by journal 07 Apr, 2021 Editor assigned by journal 07 Sep, 2020 Submission checks completed at journal 06 Sep, 2020 Editor invited by journal 06 Sep, 2020 You are reading this latest preprint version Show more versions Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-15338","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research article","associatedPublications":[],"authors":[{"id":2122078,"identity":"f88d8001-af9e-4100-b349-8c6a1a228683","order_by":0,"name":"Bin Fu","email":"","orcid":"","institution":"Zhejiang University School of Medicine First Affiliated Hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Bin","middleName":"","lastName":"Fu","suffix":""},{"id":2122079,"identity":"edd4f4d6-7e58-4c62-8ec2-dec5f801a846","order_by":1,"name":"Zhengjie Wu","email":"","orcid":"","institution":"Zhejiang University School of Medicine First Affiliated Hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Zhengjie","middleName":"","lastName":"Wu","suffix":""},{"id":2122080,"identity":"8a7b8a8a-9d2c-42ff-8ead-0f6438777186","order_by":2,"name":"Lingtong Huang","email":"","orcid":"","institution":"Zhejiang University School of Medicine First Affiliated Hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Lingtong","middleName":"","lastName":"Huang","suffix":""},{"id":2122081,"identity":"076a5e04-f9c1-4c39-877d-709762e5921e","order_by":3,"name":"Zhaohui Chai","email":"","orcid":"","institution":"zhejiang university school of medcine First affiliated hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Zhaohui","middleName":"","lastName":"Chai","suffix":""},{"id":2122082,"identity":"43a4cf3d-16d8-4139-844e-0b9f99c58b19","order_by":4,"name":"Peidong Zheng","email":"","orcid":"","institution":"zhejiang university school of medcine First affiliated hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Peidong","middleName":"","lastName":"Zheng","suffix":""},{"id":2122083,"identity":"822a9aa8-3df2-4848-b837-c35a6a0e610f","order_by":5,"name":"Qinmiao Sun","email":"","orcid":"","institution":"zhejiang university school of medcine First affiliated hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Qinmiao","middleName":"","lastName":"Sun","suffix":""},{"id":2122084,"identity":"39d0a3ff-3891-460d-b3e6-0479b069b656","order_by":6,"name":"Silan Gu","email":"","orcid":"","institution":"Zhejiang University School of Medicine First Affiliated Hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Silan","middleName":"","lastName":"Gu","suffix":""},{"id":2122085,"identity":"170e8d19-aff5-4b90-8021-3f582e0f619b","order_by":7,"name":"Qiaomai Xu","email":"","orcid":"","institution":"Zhejiang University School of Medicine First Affiliated Hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Qiaomai","middleName":"","lastName":"Xu","suffix":""},{"id":2122086,"identity":"b31b79ca-076b-4abb-b8e7-12c060245026","order_by":8,"name":"Haiting Feng","email":"","orcid":"","institution":"zhejiang university school of medcine First affiliated hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Haiting","middleName":"","lastName":"Feng","suffix":""},{"id":2122087,"identity":"32862c83-d66f-492c-a4fa-0135dd849e24","order_by":9,"name":"Lingling Tang","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA10lEQVRIiWNgGAWjYBACNmbmgw8SeCTkGBgOgLhEaOFjZ0s2+CBjY0y8Fjl+HjPBGTZpiQ0QS4lyGI8ZM0/O4fT5jWcMGD6UHWbgn91ASAtb2WOeM4dzGxvOGDDOOHeYQeLOAUJamLcb8/Yczm1mOGPAzNt2mMFAIoGQFgYzad5/h9PZQFr+EqeFxUxyBk9aAg9ICyNxWkCBzGNjOIPhWMHBnnPpPBI3CGiR7z8Mjkp5+RmHNz74UWYtxz+DgBYEkDgAjkweYtUDAX8DCYpHwSgYBaNgRAEARQY+TPOC2tsAAAAASUVORK5CYII=","orcid":"https://orcid.org/0000-0002-3033-7662","institution":"Zhejiang University School of Medicine First Affiliated Hospital Department of Infectious Diseases","correspondingAuthor":true,"submittingAuthor":false,"prefix":"","firstName":"Lingling","middleName":"","lastName":"Tang","suffix":""}],"badges":[],"createdAt":"2020-02-26 12:27:54","currentVersionCode":2,"declarations":"","doi":"10.21203/rs.2.24780/v2","doiUrl":"https://doi.org/10.21203/rs.2.24780/v2","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":13590407,"identity":"11424455-875a-4b6f-a3de-b24e113354e2","added_by":"auto","created_at":"2021-09-17 05:04:30","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":278971,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-15338/v2/eb377f20-5d77-4b2b-8a2a-72f576fbcb37.pdf"},{"id":2360785,"identity":"ac6d079e-fbd2-40ed-a703-a81e087b879e","added_by":"auto","created_at":"2020-09-11 13:55:31","extension":"doc","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":61952,"visible":true,"origin":"","legend":"","description":"","filename":"SupplementaryMaterial.doc","url":"https://assets-eu.researchsquare.com/files/rs-15338/v2/SupplementaryMaterial.doc"}],"financialInterests":"","formattedTitle":"A Comparison of Demographic, Epidemiological and Clinical Characteristics of Hospital Influenza-related Viral Pneumonia Patients","fulltext":[{"header":"Background","content":"\u003cp\u003eInfluenza causes considerable morbidity during each annual influenza season. In April 2009, the influenza A (H1N1) pdm09 (pH1N1) virus emerged in Mexico and the USA and spread globally [1]. Since the first report of pneumonia that was caused by the pH1N1 virus in Mexico [2], severe cases have been documented worldwide. Influenza B virus has been classically considered less pathogenic than influenza A virus in adults and mostly responsible for mild respiratory infections, while severe illness and poor prognosis have been associated with bacterial coinfection \u0026nbsp;[3,4]. On March 30, 2013, three individuals with severe pneumonia were found to be infected with a novel avian-origin influenza A (H7N9) virus that had not been detected in humans and animals previously. As of May 9, 2013, 131 laboratory-confirmed cases were reported, including 32 deaths [5], and the majority of these patients were reported in China.\u003c/p\u003e\n\u003cp\u003eThe comparison of the demographic, epidemiological, and clinical characteristics of hospital human influenza (influenza A (H1N1) pdm09, H3N2, and B) -related and hospitalized avian-origin influenza A (H7N9)-related viral pneumonia patients has not been reported.2017-2018 influenza season was dominated by pH1N1 and B viruses along with co-circulation of H3N2 virus, this season provided a unique opportunity to directly compare the demographic, epidemiological, and clinical characteristics of hospitalized human influenza A (pH1N1 and H3N2)-related viral pneumonia patients to the hospital influenza B-related viral pneumonia patients. Also, we compared the demographic, epidemiological, and clinical characteristics of these hospitalized human influenza (pH1N1, H3N2, and B)-related viral pneumonia patients to the hospital H7N9-related viral pneumonia patients in 2017, and aimed to discover the factors independently associated with invasive mechanical ventilation (IMV) or death among these three types hospitalized influenza-related viral pneumonia patients.\u003cbr /\u003e \u003c/p\u003e"},{"header":"Methods","content":"\u003cp\u003eStudy Design and Study Population\u003c/p\u003e\n\u003cp\u003eA retrospective study was conducted from November 1, 2017 to March 31, 2018 at the First Affiliated Hospital, College of Medicine, Zhejiang University, China. All patients, \u0026gt;14 years of age and with hospital stay \u0026gt;24 h with confirmed human influenza A or B-related viral pneumonia were included in this study. In addition to above factors, those with confirmed H7N9-related viral pneumonia from January 1, 2017 to May 3, 2017 were also included. This study was approved by the Ethical Board of the hospital.\u003c/p\u003e\n\u003cp\u003eThis retrospective study evaluated the reverse transcriptase-polymerase chain reaction (RT-PCR) tests and computed tomography results daily in hospitalized patients with confirmed human influenza A- or B-related viral pneumonia or H7N9-related viral pneumonia. These cases were assessed by an Infectious Disease doctor and nasopharyngeal swabs (NPS) or sputum specimens were collected within the first 24 h of hospitalization and processed immediately. Influenza-related viral pneumonia was defined as confirmed human influenza A or B or H7N9 virus infection and the presence of a new infiltrate on computed tomography plus fever or respiratory symptoms. All radiological evaluations were performed by two radiologists who were blinded to the clinical information.\u003c/p\u003e\n\u003cp\u003eData Collection and Definitions\u003c/p\u003e\n\u003cp\u003eClinical data were acquired from electronic medical records. The following variables were recorded: demographics, comorbid conditions, current smoking status, alcohol abuse, pregnancy, body mass index (BMI), clinical feature, laboratory data, radiographic finding, complication, treatment, and clinical outcome. The definitions of obesity, current smoking status, alcohol abuse, confirmed human influenza A or B, confirmed H7N9, lymphocytopenia, thrombocytopenia, rhabdomyolysis, acute kidney injury, immunosuppression, early antiviral therapy, exposure to live poultry and severe cases were provided in the Supplementary Appendix.\u003c/p\u003e\n\u003cp\u003eStatistical Analysis\u003c/p\u003e\n\u003cp\u003eCategorical variables were compared by the chi-square or Fisher\u0026rsquo;s exact test. Continuous variables were compared by the t-test or the Mann\u0026ndash;Whitney test. The multivariate logistic regression analysis of factors potentially associated with IMV or in-hospital mortality included the variables that were significant in the univariate analysis and clinically important variables. Statistical significance was established at p-value \u0026lt;0.05. All statistical analyses were performed using SPSS v.18. (SPSS Inc., Chicago, IL, USA).\u003c/p\u003e"},{"header":"Results","content":"\u003cp\u003eDemographic and Epidemiological Characteristics\u003c/p\u003e\n\u003cp\u003eFrom November 1, 2017 to March 31, 2018, a total of 4,297 cases of laboratory-confirmed human influenza A and B viral infection were reported in our hospital. Of these, 2335 cases were human influenza A (about 85% were pH1N1 and 15% were H3N2), 1880 cases were influenza B, and 82 cases were infected with both viruses. Finally, 138 cases of hospitalized human influenza A-related viral pneumonia and 59 cases of hospitalized influenza B-related viral pneumonia were included in this study. From January 1 ,2017 to May 3 , 2017, a total of 18 cases of hospitalized H7N9 -related viral pneumonia were also included in the current study. The median age of hospitalized human influenza A-related viral pneumonia patients was lower than those with B pneumonia (57 years (interquartile range (IQR), 45.8\u0026ndash;66.3) \u003cem\u003evs\u003c/em\u003e. 62 years (IQR, 53\u0026ndash;74); p=0.034). In the 35\u0026ndash;49-year-old age group, the proportion of hospitalized human influenza A-related viral pneumonia patients was 23.9%, which was higher than B pneumonia patients (10.2%; p=0.027). In the \u0026ge;65-year-old group, the proportion of hospitalized human influenza A-related viral pneumonia patients was 32.6%, which was relatively lower than B pneumonia patients (45.8%; p=0.079;Table 1). The proportion of comorbid conditions in hospitalized human influenza A-related viral pneumonia patients was 58%, which was lower than the B pneumonia patients and hospitalized H7N9 pneumonia patients (78% \u003cem\u003evs\u003c/em\u003e. 77.8%; p=0.013). Interestingly, 66.7% of hospitalized H7N9-related viral pneumonia patients were exposed to live poultry.\u003c/p\u003e\n\u003cp\u003eClinical Characteristics and Diagnostic Findings\u003c/p\u003e\n\u003cp\u003eThe most common symptoms of the three types of hospital influenza-related viral pneumonia patients were fever, cough, sputum production, shortness of breath, and fatigue(Table 2)..\u003c/p\u003e\n\u003cp\u003eAt the time of admission, the proportion of lymphocytopenia in hospitalized human influenza A-related viral pneumonia patients was 83.3%, higher than B pneumonia patients (69.5%; p=0.028). The proportion of elevated \u0026nbsp;aspartate aminotransferase (AST), lactate dehydrogenase (LDH) in hospitalized human influenza A-related viral pneumonia patients was higher than that of B pneumonia patients (46.7% \u003cem\u003evs\u003c/em\u003e. 25.9%, p=0.007; 67.9% \u003cem\u003evs\u003c/em\u003e. 51%, p=0.033). The median value of lymphocyte count in hospitalized H7N9-related viral pneumonia patients was 425/mm\u003csup\u003e3\u003c/sup\u003e (IQR: 375 \u0026ndash;625), lower than human influenza A and B pneumonia patients (745/mm\u003csup\u003e3\u003c/sup\u003e (IQR: 448\u0026ndash;1208) \u003cem\u003evs\u003c/em\u003e. 1020/mm\u003csup\u003e3\u003c/sup\u003e (IQR: 550\u0026ndash;1690); p=.001). The proportion of lymphocytopenia in hospitalized H7N9-related viral pneumonia patients was 100.0%, higher than human influenza A and B pneumonia patients (83.3% \u003cem\u003evs\u003c/em\u003e. 69.5%; p=0.006). The proportion of elevated AST, creatine kinase (CK), DD, and LDH in hospitalized H7N9-related viral pneumonia patients was higher than human influenza A and B pneumonia patients (77.8% \u003cem\u003evs\u003c/em\u003e. 46.7% \u003cem\u003evs\u003c/em\u003e. 25.9%, p\u0026lt;0.001; 76.5% \u003cem\u003evs\u003c/em\u003e. 17.9% \u003cem\u003evs\u003c/em\u003e. 9.8%, p\u0026lt;0.001; 94.4% \u003cem\u003evs\u003c/em\u003e. 76.5% \u003cem\u003evs\u003c/em\u003e. 62.5%, p=0.016; 100% \u003cem\u003evs\u003c/em\u003e. 67.9% \u003cem\u003evs\u003c/em\u003e. 51%, p=0.001). The proportion of positive culture (blood or sputum) on presentation or during hospitalization in the hospitalized H7N9-related viral pneumonia patients (bacterial) was 61.1%, higher than the human influenza A and B pneumonia patients (21.1% \u003cem\u003evs\u003c/em\u003e. 21.3%; p=0.002)\u003c/p\u003e\n\u003cp\u003eComplications, Treatment, and Clinical Outcomes\u003c/p\u003e\n\u003cp\u003eIn the current study, the proportion of intensive care unit (ICU) admission in hospitalized human influenza A-related viral pneumonia patients was 19.6%, which higher than 6.8% of B pneumonia patients (p=0.024). The proportion of IMV in hospitalized human influenza A-related viral pneumonia patients was 16.7%, which also higher than that in B pneumonia patients 3.4% (p=0.01) (Table 3). The proportion of IMV in hospitalized H7N9-related viral pneumonia patients was 38.9%, which was higher than that in human influenza A and B pneumonia patients (16.7% \u003cem\u003evs\u003c/em\u003e. 3.4%; p=0.001). The median value of hospital expense of hospitalized H7N9-related viral pneumonia patients was 66095.6 Yuan (IQR, 42450.6\u0026ndash;129574.2), which was higher than that of human influenza A and B pneumonia patients (IQR, 25642.3 Yuan (13184.5\u0026ndash;53805.7) \u003cem\u003evs\u003c/em\u003e. 18316.8 Yuan (IQR, 11111.1\u0026ndash;35750.5); p\u0026lt;0.001). There was no difference in death to three types of hospitalized influenza-related viral pneumonia patients.\u003c/p\u003e\n\u003cp\u003eIn the treatment, the rate of glucocorticoid use in hospitalized H7N9-related viral pneumonia patients was 100%, which was higher than human influenza A and B pneumonia patients (55.8% \u003cem\u003evs\u003c/em\u003e. 40.7%; p\u0026lt;0.001). All the hospitalized human influenza A-related viral pneumonia patients and hospitalized influenza B-related viral pneumonia patients were treated with aseltamivir or peramivir or both, and all the hospitalized H7N9-related viral pneumonia patients were treated with a combination of aseltamivir with peramivir. However, the time from onset of illness to administration of antiviral therapy in hospitalized H7N9-related viral pneumonia patients was 4 days (IQR, 3\u0026ndash;8.3), which was relatively shorter than that of human influenza A and B pneumonia patients (7 days (IQR, 5\u0026ndash;10.8) \u003cem\u003evs\u003c/em\u003e. 6 days (range, 3\u0026ndash;14); p=0.089). The time of administration of antiviral therapy to virus-negative time of hospitalized H7N9-related viral pneumonia patients was 5.5 days (IQR, 2.8\u0026ndash;10), shorter than human influenza A and B pneumonia patients (10 days (IQR, 6\u0026ndash;14.5) \u003cem\u003evs\u003c/em\u003e. 11 days (IQR, 6\u0026ndash;17.75); p=0.007).\u003c/p\u003e\n\u003cp\u003eFactors associated with IMV due to Three Types Hospitalized Influenza-related Viral Pneumonia Patients\u003c/p\u003e\n\u003cp\u003eIn the univariate analysis, the three types hospitalized influenza-related viral pneumonia patients with IMV had significantly higher neutrophil percentage, C-reactive protein, AST, DD, blood urea nitrogen, pro-B-type natriuretic peptides, and partial pressure arterial oxygen/fraction of inspired oxygen (PaO\u003csub\u003e2\u003c/sub\u003e:FiO\u003csub\u003e2\u003c/sub\u003e) levels than the three types hospitalized influenza-related viral pneumonia patients without IMV. Furthermore, the proportion of patients with shortness of breaths, lymphocytopenia, elevated procalcitonin, AST, CK, DD, and LDH, positive bacterial culture (sputum) on presentation or during hospitalization, positive bacterial culture (blood or sputum) on presentation or during hospitalization, CURB-65 score \u0026ge;2, bilateral pneumonia, and pulmonary consolidation in the three types of hospitalized influenza-related viral pneumonia patients with IMV was significantly higher than those without IMV, while the lymphocyte\u0026nbsp;count in the three types of pneumonia patients with IMV was lower than those without IMV (Table S1 in the Supplementary Material). In the multivariate analysis, pulmonary consolidation (odds ratio (OR): 13.67; 95% confidence interval (CI): 1.54\u0026ndash;121.12; p=0.019) and positive bacterial culture (sputum) at the time of presentation or during hospitalization (OR: 7.71; 95% CI: 2.48\u0026ndash;24.03; p\u0026lt;0.001) were independently associated with IMV in the three types hospitalized influenza-related viral pneumonia patients(Table S3 in the Supplementary Material).\u003c/p\u003e\n\u003cp\u003eFactors Associated with Death due to the three Types Hospitalized Influenza-related Viral Pneumonia Patients\u003c/p\u003e\n\u003cp\u003eIn the univariate analysis, the three types of hospitalized influenza-related viral pneumonia patients who die in the hospital had significantly higher neutrophil percentage, hemoglobin, blood platelet counts, C-reactive protein, DD, blood urea nitrogen, pro-B-type natriuretic peptides, and PaO\u003csub\u003e2\u003c/sub\u003e:FiO\u003csub\u003e2\u003c/sub\u003e levels than the survivors. Also, the proportion of elevated white blood cell count and procalcitonin, positive bacterial culture (sputum) on presentation or during hospitalization, CURB-65 score \u0026ge;2, IMV, shock to the three types hospitalized influenza-related viral pneumonia patients who die in the hospital was significantly higher than that of the survivors (Table S2 in the Supplementary Material). In the multivariate analysis, shock (OR: 13.16; 95% CI: 2.06\u0026ndash;84.07; p=0.006), white blood cell count \u0026gt;10,000/mm\u003csup\u003e3\u003c/sup\u003e (OR: 7.22; 95% CI: 1.47\u0026ndash;35.58; p=0.015) and positive bacterial culture(blood or sputum) on presentation or during hospitalization (OR: 6.27; 95% CI: 1.36\u0026ndash;28.85; p=0.018) were independently associated with death in the three types hospitalized influenza-related viral pneumonia patients (Table 4).\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eThis was the first study that compared the demographic, epidemiological, and clinical characteristics of hospitalized human influenza-related viral pneumonia patients with H7N9 pneumonia patients. The study revealed that the hospitalized human influenza A-related viral pneumonia patients were younger than those with B pneumonia, and the infection was primarily detected in young adults. On the other hand, the influenza B-related viral pneumonia was common in the elderly, usually with comorbid conditions. Hospitalized human influenza A-related viral pneumonia patients was severer than B pneumonia patients,but milder than H7N9 pneumonia patients.\u003c/p\u003e\n\u003cp\u003eThe proportion of patients who have at least one comorbid condition in those with human influenza A-related viral pneumonia was lower than those with B pneumonia and H7N9 pneumonia patients. Moreover, the average age of hospitalized human influenza A-related viral pneumonia patients was lower than that of B pneumonia patients, and the proportion of the hospitalized human influenza A-related viral pneumonia patients in the 35\u0026ndash;49 age group was more than that of the B pneumonia patients, and the proportion in the \u0026ge;65 years age group was relatively less than that of the B pneumonia patients. Some studies have reported that influenza B mainly affects the elderly and people with underlying diseases [6,7]; however, pH1N1 mainly affects\u0026nbsp;young adults, similar to our research. Early-life exposure to an antigenically related virus, i.e., the A (H1N1) strain that circulated after the 1918 pandemic and prior to the 1957 A (H2N2) pandemic might mitigate the severity for the pH1N1 strain in older individuals; this phenomenon explained the survival of elderly in the pandemic.In china,the old people retire at 60 years of age and have more opportunities to shop in live-animal markets, therefore more likely to be exposed to the live-poultry, it can partially explain why the H7N9 patients have more comorbid conditions.\u003c/p\u003e\n\u003cp\u003eIn the aspect of clinical characteristics and diagnostic findings, CK was designated as a biomarker of severity in pH1N1 infection; the elevation of CK was associated with complications, increased length of ICU stay, and healthcare resources [8]. Another study included 155 hospitalized adult patients with pH1N1; LDH was an independent risk factor of hospital death as assessed by multivariate logistic regression analysis [9]. The elevation of DD may be caused by the embolism of the small pulmonary vessels, then the pulmonary ventilation and blood flow ratio became abnormal, and the blood oxygen saturation declined. Finally, the rate of mortality was elevated; however, this hypothesis needs further substantiation. A lymphocyte count of \u0026lt;300 lymphocytes/mL was observed in a subgroup of patients with poor outcome in a study encompassing 239 inpatients with confirmed influenza virus infection [10]. Thus, we can conclude that the proportion of elevated CK, LDH, DD, and lymphocytopenia was positively relative to the severity of influenza. In this study, the elevated LDHand lymphocytopenia in hospitalized human influenza A-related viral pneumonia patients was higher than that in B pneumonia patients, and the elevated CK, LDH, DD, and lymphocytopenia in hospitalized H7N9-related viral pneumonia patients was higher than that in human influenza A and B pneumonia patients. The proportion of ICU admission and invasive mechanical ventilation in hospitalized human influenza A-related viral pneumonia patients was higher than that in B pneumonia patients. The proportion of IMV and the median value of hospitalization expense in hospitalized H7N9-related viral pneumonia patients were higher than that in human influenza A and B pneumonia patients. Taken together, it can be concluded that the hospitalized human influenza A-related viral pneumonia patients was severer than B pneumonia patients,but milder than H7N9 pneumonia patients. A study consisting of 57 cases of H7N9 patients and 14 cases of pH1N1 patients demonstrated that the proportion of acute respiratory distress syndrome to H7N9 was much higher than that of pH1N1 [11], which was also observed in the current study. Furthermore, the proportion of ICU admission and IMV to pH1N1 was 2-fold higher than that of B, and no difference was detected in the mortality as reported by a study including 2791 cases of adult patients[12]. Another study reported that the mortality of adults influenza B patients was similar to that of pH1N1 patients [13]. Although all the influenza viruses infect the respiratory epithelium from the nasal passages to bronchioles, pH1N1 tends to infect pneumocytes and interalveolar macrophages, causing extensive areas of inflammation in the alveoli, which could partially explain the increased severity of pH1N1 [14-17]. Hospitalized influenza B-related viral pneumonia mainly affects the elderly and those with underlying diseases, rendering them as severe cases, such that the mortality of B pneumonia patients was elevated and similar to human influenza A pneumonia patients. Hypercytokinemia is characterized by the over-production of various proinflammatory cytokines and plays an significant role in disease severity and mortality in H5N1 patients [18]. Compared with pH1N1 infection, H7N9 virus infection tends to induce higher cytokine expression, resembling the cytokine storm observed in H5N1 infection[19]，which could partially explain why the H7N9 infection was severer than pH1N1. \u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThe World Health Organization Guidelines recommended that prompt empirical antiviral treatment should be initiated when influenza is suspected, even before laboratory results are known[20]. Improved clinical outcomes have been described among adults treated with antiviral drugs after hospitalization or up to 5 days from illness onset [21-23]. Early antiviral therapy within 2\u0026nbsp;days of illness accelerated viral shedding and reduced the mortality in patients with H7N9 viral infection [24]. Moreover, compared to early antiviral therapy, H7N9 patients with delayed antiviral therapy became severe cases [25]. Interestingly, in a study comprising of 82 cases of H7N9 virus infection, the time of onset of illness to administration of antiviral therapy was 6 days (IQR: 4\u0026ndash;8), longer than that in the current study 4 days (IQR:3\u0026ndash;8.3), and the administration of antiviral therapy to virus-negative time of the study was 7 days (IQR: 5\u0026ndash; 9), also longer than 5.5 days (IQR: 2.8\u0026ndash;10) in the current study; the mortality was 34.1% [26]. Gao et al. [27] reported that the rate of glucocorticoid use of the H7N9 cases was 62.2%, lower than our study 100% and the mortality was 27%. The mortality of hospitalized H7N9-related viral pneumonia patients was much higher than that of human influenza A and B pneumonia. However, in the current study, the mortality of hospitalized H7N9-related viral pneumonia patients was lower than before and similar to human influenza A and B pneumonia. This phenomenon might be explicated by the initial antiviral time relatively early than before and the rate of glucocorticoid use for H7N9 was high. All our patients received oseltamivir with peramivir that also may reduce the mortality, although these findings need to be substantiated further. In the current study, the proportion of early antiviral therapy in the three types of hospitalized influenza-related viral pneumonia patients was similar.\u003c/p\u003e\n\u003cp\u003eNevertheless, the present study has several limitations. First, influenza testing was ordered at the physicians\u0026rsquo; discretion, and therefore, not all individuals with influenza were tested, or testing could be biased towards severe cases. However, this bias would not affect our main findings because influenza testing was ordered independently of the knowledge of the virus type or subtype. Second, we only included the hospitalized influenza-related viral pneumonia patients and excluded the outpatient cases and hospitalized patients without influenza-related viral pneumonia, such that it cannot reflect the whole disease spectrum. Finally, because the RT-PCR was not accurate absolutely, the real influenza-positive patients may be diagnosed as negative.\u003c/p\u003e"},{"header":"Conclusion","content":"\u003cp\u003eIn summary, hospitalized influenza B-related viral pneumonia mainly affects the elderly and individuals with underlying diseases, while human influenza A pneumonia mainly affects the young adults; however, the mortality was comparative. The hospitalized human influenza A-related viral pneumonia patients was severer than B pneumonia patients,but milder than H7N9 pneumonia patients. Pulmonary consolidation and positive bacterial culture(sputum) at the time of presentation or during hospitalization were independently associated with IMV due to three types of hospital influenza-related viral pneumonia patients. On the other hand, shock, white blood cell count \u0026gt;10,000/mm\u003csup\u003e3\u003c/sup\u003e, and positive bacterial culture (blood or sputum) at the time of presentation or during hospitalization were associated with death in such patients.\u003c/p\u003e"},{"header":"Abbreviations","content":"\u003cp\u003eIMV: invasive mechanical ventilation; pH1N1: influenza A (H1N1) pdm09; H7N9: avian-origin influenza A(H7N9); RT-PCR: reverse transcriptase-polymerase chain reaction; NPS: nasopharyngeal swabs; BMI: body mass index; IQR: interquartile range; AST: aspartate aminotransferase; LDH: lactate dehydrogenase; DD: d-dimer ; CK: creatine kinase; ICU: intensive care unit; ECMO: extracorporeal membrane oxygenation; PaO2:FiO2: partial pressure arterial oxygen/fraction of inspired oxygen; OR: odds ratio; CI: confidence interval; SCr: serum creatinine\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eAcknowledgments\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eWe acknowledge the contributions of other clinical and technical staff of the First Affiliated Hospital, College of Medicine, Zhejiang University.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis work was supported by grants from the Natural\u0026nbsp;Science\u0026nbsp;Foundation\u0026nbsp;of\u0026nbsp;China (No. 81872672) and National Science and Technology Major Project (No. 2017ZX10204401).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAvailability of data and materials\u003c/strong\u003e\u003cbr /\u003e All data generated or analysed during this study are either included in this published article and its supplementary information files or are available from the corresponding author on reasonable request.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors\u0026rsquo; contributions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eStudy concept and design: Bin Fu and Lingling Tang. Acquisition of data: Bin Fu, Zhengjie Wu, Lingtong Huang, Zhaohui Chai, and Peidong Zheng. Analysis and interpretation of data: Bin Fu ,Zhengjie Wu, and Lingling Tang. Drafting of the manuscript: All authors. Critical revision of the manuscript for intellectual content: All authors. All authors agree with the submission.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors details\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e1\u003c/sup\u003eState Key Laboratory for Diagnosis and Treatment of Infectious Disease, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Centre for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou310003, P.R.China.\u003csup\u003e2\u003c/sup\u003eDepartment of\u0026nbsp; Critical Care Medicine, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou310003, P.R.China.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e3\u003c/sup\u003eDepartment of\u0026nbsp; Neurosurgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou310003, P.R.China. \u003csup\u003e4\u003c/sup\u003eDepartment of\u0026nbsp; Dermatology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou310003, P.R.China. \u003csup\u003e5\u003c/sup\u003eDepartment of\u0026nbsp; Nosocomial infection，The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou310003, P.R.China.\u003csup\u003e6\u003c/sup\u003eDepartment of\u0026nbsp; Infectious Diseases, the Hangzhou Hosipital of Traditional Chinese Medicine. \u003csup\u003e7\u003c/sup\u003eShulan(Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College,Hangzhou310006, P.R.China.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interests\u003c/strong\u003e\u003cbr /\u003e The authors declare that they have no competing interests.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for publication\u003c/strong\u003e\u003cbr /\u003e Not applicable.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEthics approval and consent to participate\u003c/strong\u003e\u003cbr /\u003e The local ethics committee (The First Affiliated Hospital, College of Medicine, Zhejiang University) approved this study.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eBrammer L, Blanton L, Epperson S, et al. Surveillance for influenza during the 2009 influenza A (H1N1) pandemic-United States, April 2009\u0026ndash;March 2010. Clin Infect Dis 2011; 52:S27\u0026ndash;35.\u003c/li\u003e\n\u003cli\u003ePerez-Padilla R , de la Rosa-Zamboni D , Ponce de Leon S , et al ; INER Working Group on Influenza . Pneumonia and respiratory failure from swine-origin infl uenza A (H1N1) in Mexico . N Engl J Med. 2009 ; 361 ( 7 ): 680 - 689 .\u003c/li\u003e\n\u003cli\u003eAebi T, Weisser M, Bucher E, Hirsch HH, Marsch S, Siegemund M. Co-infection of influenza B and Streptococci causing severe pneumonia and septic shock in healthy women. BMC Infect Dis 2010;10:308 (1471-2334 (Linking)).\u003c/li\u003e\n\u003cli\u003eKim YH, Kim HS, Cho SH, Seo SH. Influenza B virus causes milder pathogenesis and weaker inflammatory responses in ferrets than influenza A virus. Viral Immunol 2009;22(6):423e30.\u003c/li\u003e\n\u003cli\u003eNumber of confirmed human cases of avian influenza A(H7N9) reported to WHO. Geneva: World Health Organization, May 2013 (\u003ca href=\"http://www.who.int/\"\u003ehttp://www.who.int/\u003c/a\u003e influenza/human_animal_interface/influenza_h7n9/05_ReportWebH7N9Number.pdf).\u003c/li\u003e\n\u003c/ol\u003e\n\u003col start=\"6\"\u003e\n\u003cli\u003eThompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, et al. Influenza-associated hospitalizations in the United States. JAMA 2004;292(11):1333e40.\u003c/li\u003e\n\u003cli\u003eTreanor JJ. Virus de la gripe. In: In: Mandell GL, Bennett JE, Dolin R, editors. Enfermedades infecciosas: principios y practica . 6th ed., vol. 2. Madrid: Elsevier INC; 2005. p. 2060e85.\u003c/li\u003e\n\u003cli\u003eBa\u0026acute;rbara Borgatta，Marcos Pe \u0026acute;rez，Loreto Vidaur, et al. Elevation of creatine kinase is associated with worse outcomes in 2009 pH1N1 influenza A infection. Intensive Care Med (2012) 38:1152\u0026ndash;1161.\u003c/li\u003e\n\u003cli\u003eXiuming Xi, Yuan Xu, Li Jiang , et al. Hospitalized adult patients with 2009 influenza A(H1N1) in Beijing, China: risk factors for hospital mortality. BMC Infectious Diseases 2010, 10:256.\u003c/li\u003e\n\u003cli\u003eAntonio Lalueza, Dolores Folgueira, Carmen D\u0026iacute;az-Pedroche, et al. Severe lymphopenia in hospitalized patients with influenza virus infection as a marker of a poor outcome, Infectious Diseases. 2019; VOL. 51,NO. 7, 543\u0026ndash;546.\u003c/li\u003e\n\u003cli\u003e11. Wenrui Wu, Ding Shi, Daiqiong Fang, et al. A new perspective on C-reactive protein in H7N9 infections. International Journal of Infectious Diseases 44 (2016) 31\u0026ndash;36.\u003c/li\u003e\n\u003cli\u003eSandra S. Chaves, Deborah Aragon, Nancy Bennett, et al. Patients Hospitalized With LaboratoryConfirmed Influenza During the 2010\u0026ndash;2011 Influenza Season: Exploring Disease Severity by Virus Type and Subtype. The Journal of Infectious Diseases 2013;208:1305\u0026ndash;14.\u003c/li\u003e\n\u003cli\u003eA. Gutie\u0026acute;rrez-Pizarraya, P. Pe\u0026acute;rez-Romero, R. Alvarez,et al. Unexpected severity of cases of influenza B infection in patients that required hospitalization during the first postpandemic wave. Journal of Infection (2012) 65, 423e430.\u003c/li\u003e\n\u003cli\u003eHuang SS, Banner D, Fang Y, et al. Comparative analyses of pandemic H1N1 and seasonal H1N1, H3N2, and influenza B infections depict distinct clinical pictures in ferrets. PLoS One 2011; 6:e27512.\u003c/li\u003e\n\u003cli\u003eGuarner J, Falc\u0026oacute;n-Escobedo R. Comparison of the pathology caused by H1N1, H5N1, and H3N2 influenza viruses. Arch Med Res 2009; 40: 655\u0026ndash;61.\u003c/li\u003e\n\u003cli\u003eItoh Y, Shinya K, Kiso M, et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 2009; 460: 1021\u0026ndash;5.\u003c/li\u003e\n\u003cli\u003eMunster VJ, de Wit E, van den Brand JM, et al. Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in ferrets. Science 2009; 325:481\u0026ndash;3.\u003c/li\u003e\n\u003cli\u003eZhou J, Wang D, Gao R, Zhao B, Song J, Qi X, et al. Biological features of novel avian influenza A (H7N9) virus. Nature 2013;499:500\u0026ndash;3\u003c/li\u003e\n\u003cli\u003ede Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, Chau TN, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load andhypercytokinemia. Nat Med 2006;12:1203\u0026ndash;7\u003c/li\u003e\n\u003cli\u003eCenters for Disease Control and Prevention. Antiviral agents for the treatment and chemoprophylaxis of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2011; 60:1\u0026ndash;24.\u003c/li\u003e\n\u003cli\u003eLee N, Choi KW, Chan PK, et al. Outcomes of adults hospitalised with severe influenza. Thorax 2010; 65:510\u0026ndash;5.\u003c/li\u003e\n\u003cli\u003eMcGeer A, Green KA, Plevneshi A, et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 2007; 45:1568\u0026ndash;75.\u003c/li\u003e\n\u003cli\u003eLouie JK, Yang S, Acosta M, et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. Clin Infect Dis 2012; 55:1198\u0026ndash;204.\u003c/li\u003e\n\u003cli\u003eShufa\u0026nbsp;Zheng, Lingling\u0026nbsp;Tang, Hainv\u0026nbsp;Gao, et al. Benefit of Early Initiation of Neuraminidase Inhibitor Treatment to Hospitalized Patients With Avian Influenza A(H7N9)\u0026nbsp;Virus. Clinical Infectious Diseases 2018;66(7):1054\u0026ndash;60.\u003c/li\u003e\n\u003cli\u003eLeung YH, To MK, Lam TS, Yau SW, Leung OS, Chuang SK. Epidemiology of human influenza A(H7N9) infection in Hong Kong. J Microbiol Immunol Infect. 2015;S1684-1182(15)00772-0.\u003c/li\u003e\n\u003cli\u003eYan Zhang, Hainv Gao, Weifeng Liang, et al.Efficacy of oseltamivir-peramivir combination therapy compared to oseltamivir monotherapy for Influenza A (H7N9) infection: a retrospective study. BMC Infectious Diseases (2016) 16:76.\u003c/li\u003e\n\u003cli\u003e27. Hai-Nv Gao, Hong-Zhou Lu, Bin Cao,et al. Clinical Findings in 111 Cases of Influenza A (H7N9) Virus Infection. N Engl J Med 2013;368:2277-85.\u003c/li\u003e\n\u003c/ol\u003e"},{"header":"Tables","content":"\u003ctable style=\"border-collapse:collapse;border:none;\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 474.15pt;border-top: none;border-right: none;border-left: none;border-image: initial;border-bottom: 1pt solid windowtext;padding: 0in 5.4pt;height: 6pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cstrong\u003e\u003cspan style='font-size:12px;font-family:\"Times New Roman\",serif;color:black;'\u003eTable 1\u0026nbsp;\u003c/span\u003e\u003c/strong\u003e\u003cspan style='font-size:12px;font-family:\"Times New Roman\",serif;color:black;'\u003eComparison of Demographic and Epidemiological Characteristics of three types Hospitalized Influenza-related Viral\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"Times New Roman\",serif;color:black;'\u003e\u003cbr\u003e\u0026nbsp;\u003c/span\u003e\u003cspan style='font-size:12px;font-family: \"Times New Roman\",serif;color:black;'\u003ePneumonia Patients\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 474.15pt;border-top: none;border-right: none;border-left: none;border-image: initial;border-bottom: 1pt solid windowtext;padding: 0in 5.4pt;height: 9pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eCharacteristics \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;B (\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-I\",serif;color:black;'\u003en\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvPS3FDD77\",serif;color:black;'\u003e=59\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; A (\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-I\",serif;color:black;'\u003en\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvPS3FDD77\",serif;color:black;'\u003e=138\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;H7N9 (\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-I\",serif;color:black;'\u003en\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvPS3FDD77\",serif;color:black;'\u003e=18\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-I\",serif;color:black;'\u003ep\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e-value among \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:9.0pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;(a) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; (b) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; (c) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; (a) and (b) \u0026nbsp;(a), (b), and (c)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 474.15pt;border-top: none;border-right: none;border-left: none;border-image: initial;border-bottom: 1pt solid windowtext;padding: 0in 5.4pt;height: 9pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eDemographic data\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:13.5pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eAge (y)\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvOT7e24f250\",serif;color:#231F20;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:13.5pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvOT7e24f250\",serif;color:#231F20;'\u003emedian (IQR)\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;62 (53\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026ndash;\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e74) \u0026nbsp; \u0026nbsp; \u0026nbsp;57 (45.8\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026ndash;\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e66.3) \u0026nbsp; \u0026nbsp; \u0026nbsp;60 (43.3\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026ndash;\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e68) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.034 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.095\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:13.5pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eAge subgroup (y), \u0026nbsp;no. (%)\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:22.5pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e14\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026ndash;\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e34 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;7 (11.9) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;12 (8.7) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;1 (5.6) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.490 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.752\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:22.5pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e35\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026ndash;\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e49 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;6 (10.2) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;33 (23.9) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 4 (22.2) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.027 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.080\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:22.5pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e50\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026ndash;\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e64 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 19 (32.2) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;48 (34.8) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 7 (38.9) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.726 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.863\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:22.5pt;'\u003e\u003cspan style='font-size:12px;font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026ge;\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e65 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 27 (45.8) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;45 (32.6) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 6 (33.3) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.079 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.205 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:13.5pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eFemale, no. (%) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;22 (37.3) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;49 (35.5) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 4 (22.2) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.812 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.486\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eComorbid conditions, no. (%)\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:9.0pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e\u0026nbsp;Any one condition \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 46 (78.0) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;80 (58.0) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;14 (77.8) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.007 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.013 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:13.5pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eChronic pulmonary disease \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;7 (11.9) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;20 (14.5) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 2 (11.1) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.623 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.949 \u0026nbsp;\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:13.5pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eDiabetes \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 5 (8.5) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 24 (17.4) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 2 (11.1) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.106 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.289 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:13.5pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eHypertension \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;21 (35.6) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;54 (39.1) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 8 (44.4) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.640 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.778 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:13.5pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eChronic renal diseases \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;5(8.5) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;7 (5.1) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;2 (11.1) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.556 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.327 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:13.5pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eChronic liver diseases \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;7 (11.9) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;15 (10.9) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 5 (27.8) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.839 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.132 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:13.5pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eChronic cardiovascular disease \u0026nbsp; \u0026nbsp; 5 (8.5) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 25 (18.1) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 2 (11.1) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.085 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.224 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;margin-left:13.55pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eChronic neurological disease \u0026nbsp; \u0026nbsp; 4 (6.8) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 5 (3.6) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 1(5.6) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.549 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.495 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; Hematological diseases \u0026nbsp; \u0026nbsp; \u0026nbsp; 10 (16.9) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;12 (8.7) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0 (0) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.092 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.085 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:13.5pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eImmunosuppression \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;7 (11.9) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 11 (8) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0 (0) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.385 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.305 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003ePregnancy \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0 (0) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;1 (0.7) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0 (0) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 1.000 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;1.000 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003cbr\u003e\u0026nbsp;Current smoker \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 9 (15.3) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;36 (26.1) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 7 (38.9) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.097 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.076 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eAlcohol abuse \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;8 (13.6) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;27 (19.6) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 3 (16.7) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.312 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.633 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eBMI, no. (%)\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:9.0pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eobesity+morbid obesity \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0 (0) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;7 (5.1) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0 (0) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.105 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.229 \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eExposure to live poultry in \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:4.5pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eprevious 14 days, no. (%) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;NA \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;NA \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 12 (66.7) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;line-height:150%;'\u003e\u003cspan style='font-size:12px;line-height:150%;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eAbbreviations: IQR \u0026nbsp;interquartile range\u003c/span\u003e\u003c/p\u003e\n\u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e*Overall missing data for different categories varied\u003c/span\u003e\u003c/p\u003e\n\u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eBody mass index: For human influenza A, there were 40 miss dates; for B, there were 18 miss dates; for H7N9, there were 3 miss dates\u003c/span\u003e\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003ctable style=\"width: 4.7e+2pt;border-collapse:collapse;border:none;\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 474.15pt;border-top: none;border-right: none;border-left: none;border-image: initial;border-bottom: 1pt solid windowtext;padding: 0in 5.4pt;height: 6pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cstrong\u003e\u003cspan style='font-size:12px;font-family:\"Times New Roman\",serif;color:black;'\u003eTable 2\u0026nbsp;\u003c/span\u003e\u003c/strong\u003e\u003cspan style='font-size:12px;font-family:\"Times New Roman\",serif;color:black;'\u003eComparison of Clinical Characteristics of Three Types Hospitalized Influenza-related Viral Pneumonia Patients\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 474.15pt;border-top: none;border-right: none;border-left: none;border-image: initial;border-bottom: 1pt solid windowtext;padding: 0in 5.4pt;height: 9pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eCharacteristics \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;B (\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-I\",serif;color:black;'\u003en\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvPS3FDD77\",serif;color:black;'\u003e=59\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; A (\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-I\",serif;color:black;'\u003en\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvPS3FDD77\",serif;color:black;'\u003e=138\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;H7N9 (\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-I\",serif;color:black;'\u003en\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvPS3FDD77\",serif;color:black;'\u003e=18\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-I\",serif;color:black;'\u003ep\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e-value among \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; (a) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; (b) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;(c) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;(a) and (b) \u0026nbsp;(a), (b), and (c)\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 474.15pt;border-top: none;border-right: none;border-left: none;border-image: initial;border-bottom: 1pt solid windowtext;padding: 0in 5.4pt;height: 9pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eClinical features\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:9.0pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eFever\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;margin-left:10.5pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eAny no. (%)\u003c/span\u003e\u003cspan style=\"font-size:12px;font-family:SimSun;color:black;\"\u003e \u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;54 (91.5) \u0026nbsp; \u0026nbsp; \u0026nbsp; 123 (89.1) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;17 (94.4) \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.620 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.819 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Maximal temperature subgroup, no (%)\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:4.5pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e\u0026nbsp; \u0026nbsp; 37.3\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026ndash;\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e38.0 \u0026deg;C \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;11 (20.4) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 12 (10.6) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 3 (18.8) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.046 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.173 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:22.5pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e38.1\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026ndash;\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e39.0 \u0026deg;C \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;25 (46.3) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 46 (40.7) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 6 (37.5) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.226 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.734 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:.25in;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e\u0026nbsp;\u0026gt;39.0 \u0026deg;C \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 18 (33.3) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;55 (48.7) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;7 (43.8) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.213 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.174 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:9.0pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eCough \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 52 (88.1) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 120 (87) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 17 (94.4) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.820 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.845 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:9.0pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eSputum production \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 50 (84.7) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 106 (76.8) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 16 (88.9) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.209 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.348 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:9.0pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eShortness of breath \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 29 (49.2) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;83 (60.1) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 12 (66.7) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.154 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.260 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;margin-left:9.05pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eFatigue/weakness \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;34 (57.6) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;67 (48.6) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;6 (33.3) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.243 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.175 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003cbr\u003e\u0026nbsp;Myalgia \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;4 (6.8) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;16 (11.6) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 1 (5.6) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.305 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.617 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eLaboratory findings\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;margin-left:14.25pt;text-indent:-4.5pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eWhite blood cells count/mm\u003csup\u003e3\u003c/sup\u003e, \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;margin-left:14.3pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvOT7e24f250\",serif;color:#231F20;'\u003emedian (IQR)\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;6900 (4300\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026ndash;\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e12600) \u0026nbsp;7000 (4300\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026ndash;\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e9550) \u0026nbsp;4400 (3475\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026ndash;\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e5625) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.407 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.008 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;margin-left:23.25pt;text-indent:-13.5pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eSubgroup, no. (%)\u003cbr\u003e \u0026gt;10,000/mm\u003csup\u003e3\u003c/sup\u003e 17 (28.8) 32 (23.2) 1 (5.6) 0.403 0.120 \u003cbr\u003e \u0026lt;4000/mm\u003csup\u003e3\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 13 (22) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 28 (20.3) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;7\u003c/span\u003e\u003cspan style=\"font-size:12px;font-family:SimSun;color:black;\"\u003e（\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e38.9\u003c/span\u003e\u003cspan style=\"font-size:12px;font-family:SimSun;color:black;\"\u003e）\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.782 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.224 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;margin-left:14.25pt;text-indent:-4.5pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eLymphocytes count/mm\u003csup\u003e3\u003c/sup\u003e,\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;margin-left:9.05pt;text-indent:4.5pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvOT7e24f250\",serif;color:#231F20;'\u003emedian (IQR)\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;1020(550-1690) \u0026nbsp;745(448\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026ndash;\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e1208) \u0026nbsp;425(375\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026ndash;\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e625) \u0026nbsp; \u0026nbsp; \u0026nbsp;0.340 \u0026nbsp; \u0026nbsp; 0.001 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Lymphocytopenia, no. (%) \u0026nbsp; \u0026nbsp; \u0026nbsp;41 (69.5) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 115 (83.3) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;18 (100) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.028 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.006 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;margin-left:9.75pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eHemoglobulin \u0026mdash; g/dl,\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvOT7e24f250\",serif;color:#231F20;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;margin-left:9.75pt;text-indent:4.5pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvOT7e24f250\",serif;color:#231F20;'\u003emedian (IQR)\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 117 (95\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026ndash;\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e130) \u0026nbsp; \u0026nbsp; \u0026nbsp;124 (104\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026ndash;\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e139) \u0026nbsp; \u0026nbsp; 117 (109.3\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026ndash;\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e129) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.018 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.058 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;margin-left:14.25pt;text-indent:-4.5pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003ePlatelets count/mm\u003csup\u003e3\u003c/sup\u003e, \u003cbr\u003e\u0026nbsp;\u003c/span\u003e\u003cspan style='font-size:12px;font-family: \"AdvOT7e24f250\",serif;color:#231F20;'\u003emedian (IQR)\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;159000 (107000\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026ndash;\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e251000) 164500 (103300\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026ndash;\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e250000) 139000 (93800\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026ndash;\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e173500) \u0026nbsp;0.842 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.335 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:9.0pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eThrombocytopenia, no. (%) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;26 (44.1) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;60 (43.5) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 11 (61.1) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.939 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.361 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:9.0pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eC-reactive protein\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;margin-left:5.25pt;text-indent:13.5pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e\u0026gt;10 mg/L, no. (%) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;46 (82.1) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 115 (83.9) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 16 (88.9) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.760 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.836 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:9.0pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eProcalcitonin \u0026gt;0.5 ng/mL, no. (%) 8 (25.8) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;34 (31.8) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;8 (44.4) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.525 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.401 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:9.0pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eAlanine aminotransferase\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;margin-left:5.25pt;text-indent:13.5pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e\u0026gt;40 U/L, no. (%) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 15 (25.9) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;50 (36.5) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;8 (44.4) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.150 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.229 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:9.0pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eAspartate aminotransferase \u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;margin-left:5.25pt;text-indent:13.5pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e\u0026gt;40 U/L, no. (%) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 15 (25.9) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;64 (46.7) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 14 (77.8) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.007 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026lt;0.001 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:9.0pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e\u003ca href=\"javascript%3Avoid(0);\"\u003e\u003cspan style=\"color:black;text-decoration:none;\"\u003eTotal\u003c/span\u003e\u003c/a\u003e \u003ca href=\"javascript%3Avoid(0);\"\u003e\u003cspan style=\"color:black;text-decoration:none;\"\u003ebilirubin\u003c/span\u003e\u003c/a\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;margin-left:9.05pt;text-indent:9.0pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e\u0026gt;21 \u0026mu;mol/L, no. (%) \u0026nbsp; \u0026nbsp; \u0026nbsp;5 (8.6) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 10 (7.3) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0 (0) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.982 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.585 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Creatinine \u0026gt;104 \u0026mu;mol/L\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;margin-left:9.05pt;text-indent:4.5pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e(1.5 mg/dL), no. (%) \u0026nbsp; \u0026nbsp; \u0026nbsp; 12 (20.3) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 19 (13.9) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 2 (18) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.255 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.479 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Lactate dehydrogenase\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;margin-left:9.05pt;text-indent:4.5pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e\u0026gt;250 U/L, no. (%) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;26 (51) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 91 (67.9) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;17 (100) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.033 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.001 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Creatine kinase \u0026gt;200\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;margin-left:9.05pt;text-indent:4.5pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eU/L, no. (%) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 5 (9.8) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;24 (17.9) \u0026nbsp; \u0026nbsp; \u0026nbsp;13 (76.5) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.175 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026lt;0.001 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;PaO\u003csub\u003e2\u003c/sub\u003e:FiO\u003csub\u003e2\u003c/sub\u003e (mmHg), \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:13.5pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvOT7e24f250\",serif;color:#231F20;'\u003emedian (IQR)\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 227.5 (173.5\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026ndash;\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e302.8) \u0026nbsp; \u0026nbsp;214.1 (136.6\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026ndash;\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e293.2) \u0026nbsp;171.6 (137.5\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026ndash;\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e233.3) \u0026nbsp; \u0026nbsp; 0.214 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.118 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;margin-left:9.05pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003ePaO\u003csub\u003e2\u003c/sub\u003e:FiO\u003csub\u003e2\u003c/sub\u003e\u0026nbsp;\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026le;\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e300\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;margin-left:9.05pt;text-indent:4.5pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003emmHg, no. (%) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;23 (71.9) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;75 (78.1) \u0026nbsp; \u0026nbsp; \u0026nbsp; 16 (88.9) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.470 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.410 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;D-dimer \u0026gt;700\u0026nbsp;\u003c/span\u003e\u003cspan style=\"font-size:12px;font-family:Symbol;color:black;\"\u003em\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eg/L, no. (%) \u0026nbsp; \u0026nbsp;35 (62.5) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;104 (76.5) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;17 (94.4) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.049 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.016 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:9.0pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003ePositive culture (blood or sputum) on presentation or\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;margin-left:5.25pt;text-indent:13.5pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eduring hospitalization, no. (%) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:27.0pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eBacterial \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;10 (21.3) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 24 (21.1) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;11 (61.1) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.975 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.002 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:27.0pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eFungal \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 3 (6.4) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;18 (15.8) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 6 (33.3) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.107 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.028 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eRadiographic findings\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:9.0pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eComputed tomography consistent with\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:9.0pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003epneumonia at admission, no. (%)\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;margin-left:9.75pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eInvolvement of both lungs \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 52 (88.1) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;121 (87.7) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;16 (88.9) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.929 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;1.000 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u003cbr\u003e Ground-glass opacity 12 (20.3) 49 (35.5) 10 (55.6) 0.035 0.012 \u003cbr\u003e\u0026nbsp;Consolidation \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;29 (49.2) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 88 (63.8) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;18 (100) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.056 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026lt;0.001 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:9.0pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eCURB -65 score\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026ge;\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e2 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;18 (30.5) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 38 (27.5) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 6 (33.3) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.672 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.798 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;margin-left:10.5pt;text-indent:-10.5pt;'\u003e\u0026nbsp;\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eAbbreviations: PaO\u003csub\u003e2\u003c/sub\u003e:FiO\u003csub\u003e2\u003c/sub\u003e, partial pressure arterial oxygen/fraction of inspired oxygen; IQR, interquartile range.\u003c/span\u003e\u003c/p\u003e\n\u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e*Overall missing data for different categories varied\u003c/span\u003e\u003c/p\u003e\n\u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eMaximal temperature: For human influenza A, there were 25 miss dates; for B, there were 5 miss dates; for H7N9, there were 2 miss dates\u003c/span\u003e\u003c/p\u003e\n\u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eC-reactive protein: For human influenza A, there were 2 miss dates; for B, there were 2 miss dates\u003c/span\u003e\u003c/p\u003e\n\u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eProcalcitonin: For human influenza A, there were 32 miss dates; for B, there were 28 miss dates\u003c/span\u003e\u003c/p\u003e\n\u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eAlanine aminotransferase\u003c/span\u003e\u003cspan style=\"font-size:12px;font-family:SimSun;color:black;\"\u003e：\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eFor human influenza A, there were 2 miss dates; for B, there was 1 miss date\u003c/span\u003e\u003c/p\u003e\n\u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eAspartate aminotransferase: For human influenza A, there were 2 miss dates; for B, there was 1 miss date\u003c/span\u003e\u003c/p\u003e\n\u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eTotal bilirubin: For human influenza A, there were 2 miss dates; for B, there was 1 miss date\u003c/span\u003e\u003c/p\u003e\n\u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eCreatinine: For human influenza A, there were 2 miss dates\u003c/span\u003e\u003c/p\u003e\n\u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eLactate dehydrogenase: For human influenza A, there were 5 miss dates; for B, there were 8 miss dates; for H7N9, there were 2 miss dates\u003c/span\u003e\u003c/p\u003e\n\u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eCreatine kinase: For human influenza A, there were 5 miss dates; for B, there were 8 miss dates; for H7N9, there were 2 miss dates\u003c/span\u003e\u003c/p\u003e\n\u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003ePartial pressure arterial oxygen/fraction of inspired oxygen: For human influenza A, there were 43 miss dates; for B, there were 27 miss dates\u003c/span\u003e\u003c/p\u003e\n\u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eD-Dimer: For human influenza A, there were 3 miss dates; for B, there were 3 miss dates\u003c/span\u003e\u003c/p\u003e\n\u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003ePositive culture (blood or sputum) on presentation or during hospitalization(bacterial): For human influenza A, there were 25 miss dates; for B, there were 12 miss dates\u003c/span\u003e\u003c/p\u003e\n\u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003ePositive culture (blood or sputum) on presentation or during hospitalization(fungal): For human influenza A, there were 25 miss dates; for B, there were 12 miss dates\u003c/span\u003e\u003c/p\u003e\n\u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003ctable style=\"width: 4.7e+2pt;border-collapse:collapse;border:none;\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 474.15pt;border-top: none;border-right: none;border-left: none;border-image: initial;border-bottom: 1pt solid windowtext;padding: 0in 5.4pt;height: 6pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cstrong\u003e\u003cspan style='font-size:12px;font-family:\"Times New Roman\",serif;color:black;'\u003eTable 3\u0026nbsp;\u003c/span\u003e\u003c/strong\u003e\u003cspan style='font-size:12px;font-family:\"Times New Roman\",serif;color:black;'\u003eComparison of Complications, Treatment, and Clinical Outcomes of Three Types Hospitalized Influenza-related Viral\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"Times New Roman\",serif;color:black;'\u003e\u003cbr\u003e\u0026nbsp;\u003c/span\u003e\u003cspan style='font-size:12px;font-family: \"Times New Roman\",serif;color:black;'\u003ePneumonia Patients\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 474.15pt;border-top: none;border-right: none;border-left: none;border-image: initial;border-bottom: 1pt solid windowtext;padding: 0in 5.4pt;height: 9pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eCharacteristics \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; B (\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-I\",serif;color:black;'\u003en\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvPS3FDD77\",serif;color:black;'\u003e=59\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;A (\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-I\",serif;color:black;'\u003en\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvPS3FDD77\",serif;color:black;'\u003e=138\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;H7N9 (\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-I\",serif;color:black;'\u003en\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvPS3FDD77\",serif;color:black;'\u003e=18\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-I\",serif;color:black;'\u003ep\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e-value among\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; (a) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; (b) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;(c) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;(a) and (b) \u0026nbsp;(a), (b), and (c) \u0026nbsp;\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 474.15pt;border-top: none;border-right: none;border-left: none;border-image: initial;border-bottom: 1pt solid windowtext;padding: 0in 5.4pt;height: 9pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;margin-left:4.5pt;text-indent:-4.5pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvOT7e24f250\",serif;color:#231F20;'\u003eComplications \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;7 (12) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 16 (12) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;4 (22.2) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.957 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.411 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:9.0pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvOT7e24f250\",serif;color:#231F20;'\u003eShock \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;1 (1.7) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 9 (6.5) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;1 (5.6) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.289 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.315 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;margin-left:9.75pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvOT7e24f250\",serif;color:#231F20;'\u003eAcute kidney injury \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;5 (8.5) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;11 (8) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 2 (11.1) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 1.000 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.793 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003cbr\u003e\u0026nbsp;Rhabdomyolysis \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 1 (1.7) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 1 (0.7) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;1 (5.6) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.510 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.147 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvOT7e24f250\",serif;color:#231F20;'\u003eTreatment\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:9.0pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvOT7e24f250\",serif;color:#231F20;'\u003eOxygen therapy, no. (%) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 44 (74.6) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;101 (73.2) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;18 (100) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.840 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.022 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:9.0pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvOT7e24f250\",serif;color:#231F20;'\u003eAntiviral treatment, no. (%) \u0026nbsp; \u0026nbsp; 52 (88) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;152 (93) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 18 (100) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.720 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.388 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:.25in;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvOT7e24f250\",serif;color:#231F20;'\u003eOseltamivir \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;36 (69.2) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;70 (56.5) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0 (0) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.114 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026lt;0.001 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:.25in;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvOT7e24f250\",serif;color:#231F20;'\u003ePeramivir \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 9 (17.3) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 32 (25.8) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0 (0) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.224 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.020 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:.25in;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvOT7e24f250\",serif;color:#231F20;'\u003eBoth \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 7 (13.5) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;22 (17.7) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;18 (100) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.485 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026lt;0.001 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:9.0pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvOT7e24f250\",serif;color:#231F20;'\u003eTiming from onset of illness to administration \u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:9.0pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvOT7e24f250\",serif;color:#231F20;'\u003eof antiviral therapy, median (IQR) 6 (3\u003c/span\u003e\u003cspan style='font-size:16px;font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026ndash;\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvOT7e24f250\",serif;color:#231F20;'\u003e14) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 7 (5\u003c/span\u003e\u003cspan style='font-size:16px;font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026ndash;\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvOT7e24f250\",serif;color:#231F20;'\u003e10.8) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;4 (3\u003c/span\u003e\u003cspan style='font-size:16px;font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026ndash;\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvOT7e24f250\",serif;color:#231F20;'\u003e8.3) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.797 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.089 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;margin-left:16.5pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvOT7e24f250\",serif;color:#231F20;'\u003e0\u0026ndash;2 days \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;9 (17.6) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 14 (11.3) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;1 (18) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.258 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.384 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003cbr\u003e 3\u0026ndash;5 days 12 (23.5) 31 (25) 57 (34.8) 0.837 0.091 \u003cbr\u003e\u0026nbsp;\u0026ge;6 days \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;30 (58.8) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 79 (63.7) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;8 (44.4) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.544 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.281 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:9.0pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvOT7e24f250\",serif;color:#231F20;'\u003eTiming from administration of antiviral therapy\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:13.5pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvOT7e24f250\",serif;color:#231F20;'\u003eto virus negative, median (IQR) 11 (6\u003c/span\u003e\u003cspan style='font-size:16px;font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026ndash;\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvOT7e24f250\",serif;color:#231F20;'\u003e17.75) \u0026nbsp; \u0026nbsp; \u0026nbsp;10 (6\u003c/span\u003e\u003cspan style='font-size:16px;font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026ndash;\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvOT7e24f250\",serif;color:#231F20;'\u003e14.5) \u0026nbsp; \u0026nbsp; \u0026nbsp; 5 (2.8\u003c/span\u003e\u003cspan style='font-size:16px;font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026ndash;\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvOT7e24f250\",serif;color:#231F20;'\u003e10) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.260 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.007 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:9.0pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvOT7e24f250\",serif;color:#231F20;'\u003eAdmission to ICU, no. (%) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;4 (6.8) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;27 (19.6) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 15 (83.3) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.024 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.054 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:9.0pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvOT7e24f250\",serif;color:#231F20;'\u003eMechanical ventilation\u003cbr\u003e Noninvasive 6 (10.2) 14 (10.1) 0 (0) 0.996 0.528 \u003cbr\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;Invasive \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;2 (3.4) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;23 (16.7) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;7 (38.9) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.001 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.001 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;margin-left:9.05pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvOT7e24f250\",serif;color:#231F20;'\u003eExtracorporeal membrane\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;margin-left:9.05pt;text-indent:4.5pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvOT7e24f250\",serif;color:#231F20;'\u003eoxygenation \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0 (0) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;2 (1.4) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 2 (11.1) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;1.000 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.048 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u003cbr\u003e \u003ca href=\"javascript%3Avoid(0);\"\u003e\u003cspan style=\"color:#231F20;text-decoration: none;\"\u003eBlood\u003c/span\u003e\u003c/a\u003e \u003ca href=\"javascript%3Avoid(0);\"\u003e\u003cspan style=\"color:#231F20;text-decoration:none;\"\u003epurification\u003c/span\u003e\u003c/a\u003e 4 (6.8) 3 (2.2) 2 (11.1) 0.200 0.072 \u003cbr\u003e Antibiotics 56 (94.9) 134 (97.1) 17 (94.4) 0.430 0.416 \u003cbr\u003e\u0026nbsp;Antifungal \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 22 (37.3) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 42 (30.4) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;13 (72.2) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.347 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.002 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:9.0pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvOT7e24f250\",serif;color:#231F20;'\u003eGlucocorticoids \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;24 (41) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;77 (56) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;18 (100) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.052 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026lt;0.001 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;margin-left:9.0pt;text-indent:-9.0pt;'\u003e\u003cspan style='font-size:12px;font-family: \"AdvOT7e24f250\",serif;color:#231F20;'\u003eClinical outcome \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003cbr\u003e\u0026nbsp;Death \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;5 (8.5) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;13 (9.4) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0 (0) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.833 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.542 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:9.0pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvOT7e24f250\",serif;color:#231F20;'\u003eTotal hospitalization expenses (Yuan),\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:13.5pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvOT7e24f250\",serif;color:#231F20;'\u003emedian (IQR) \u0026nbsp;18316.8 (11111.1\u003c/span\u003e\u003cspan style='font-size:16px;font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026ndash;\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvOT7e24f250\",serif;color:#231F20;'\u003e35750.5) 25642.3 (13184.5\u003c/span\u003e\u003cspan style='font-size:16px;font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026ndash;\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvOT7e24f250\",serif;color:#231F20;'\u003e53805.7) 66095.6 (42450.6\u003c/span\u003e\u003cspan style='font-size:16px;font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026ndash;\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvOT7e24f250\",serif;color:#231F20;'\u003e129574.2) 0.094 \u0026nbsp; \u0026nbsp;\u0026lt;0.001 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvOT7e24f250\",serif;color:#231F20;'\u003eAbbreviations: ICU, intensive care unit; IQR, interquartile range\u003c/span\u003e\u003cspan style='font-size:16px;font-family:\"AdvOT7e24f250\",serif;color:#231F20;'\u003e.\u003c/span\u003e\u003c/p\u003e\n\u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e*Overall missing data for different categories varied\u003c/span\u003e\u003c/p\u003e\n\u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eTiming from onset of illness to administration of antiviral therapy: For human influenza A, there were 14 miss dates; for B, there were 8 miss dates\u003c/span\u003e\u003c/p\u003e\n\u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eTiming from administration of antiviral therapy to virus negative: For human influenza A, there were 73 miss dates; for B, there were 39 miss dates\u003c/span\u003e\u003c/p\u003e\n\u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eTotal hospitalization expenses: For human influenza A, there were 14 miss dates; for B, there were 6 miss dates\u003c/span\u003e\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cstrong\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eTable 4\u003c/span\u003e\u003c/strong\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e\u0026nbsp;Multivariate Analysis of Factors Associated with Death due to Three Types Hospitalized Influenza-related Viral Pneumonia Patients\u003c/span\u003e\u003c/p\u003e\n\u003ctable style=\"border-collapse:collapse;border:none;\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 426.1pt;border-top: 1pt solid windowtext;border-left: none;border-bottom: 1pt solid windowtext;border-right: none;padding: 0in 5.4pt;height: 23.5pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eVariables \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; OR (95% CI) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;p-value\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 426.1pt;border-top: none;border-right: none;border-left: none;border-image: initial;border-bottom: 1pt solid windowtext;padding: 0in 5.4pt;height: 20.8pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eWhite blood cell count \u0026gt;10,000/mm\u003csup\u003e3\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;7.22 (1.47\u0026ndash;35.58) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.015 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eHemoglobulin (g/dL) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.100\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003ePlatelets count/mm\u003csup\u003e3\u003c/sup\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.851\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eC-reactive protein (mg/L) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.772\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eProcalcitonin \u0026gt;0.5 ng/mL \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.621 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eD-dimer \u0026gt;2100\u0026nbsp;\u003c/span\u003e\u003cspan style=\"font-size:12px;font-family:Symbol;color:black;\"\u003em\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eg/L \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.387\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003ePro-B-type natriuretic peptides (pg/mL) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.231\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003ePositive bacterial culture (blood or sputum) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;6.27 (1.36\u003c/span\u003e\u003cspan style='font-size:16px;font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026ndash;\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e28.85) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.018 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:9.0pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eon presentation or during hospitalization \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eComputed tomography consistent with \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;0.427 \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;text-indent:9.0pt;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003epulmonary consolidation at admission\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eShock* \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;13.16 (2.06\u003c/span\u003e\u003cspan style='font-size:16px;font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026ndash;\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e84.07) \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; 0.006 \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e*\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eShock \u0026nbsp;Shock at any point during the illness\u003c/span\u003e\u003c/p\u003e\n\u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003eAbbreviations: OR \u0026nbsp;odds ratio\u003c/span\u003e\u003cspan style=\"font-size:12px;font-family:SimSun;color:black;\"\u003e，\u003c/span\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e\u0026nbsp;CI \u0026nbsp;confidence interval\u003c/span\u003e\u003c/p\u003e\n\u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003e*Overall missing data for different categories varied\u003c/span\u003e\u003c/p\u003e\n\u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:12px;font-family:\"AdvTrebu-R\",serif;color:black;'\u003ePro-B-type natriuretic peptides: For human influenza A, there were 62 miss dates; for B, there were 42 miss dates; for H7N9, there were 11 miss dates\u003c/span\u003e\u003c/p\u003e\n\u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;'\u003e\u0026nbsp;\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"bmc-infectious-diseases","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"infd","sideBox":"Learn more about [BMC Infectious Diseases](http://bmcinfectdis.biomedcentral.com/)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/infd","title":"BMC Infectious Diseases","twitterHandle":"#bmcinfectdis","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"em","reportingPortfolio":"BMC Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"human influenza A, influenza B, avian-origin influenza H7N9, viral pneumonia, severe cases","lastPublishedDoi":"10.21203/rs.2.24780/v2","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.2.24780/v2","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eObjective: Through the comparison of the demographic, epidemiological, and clinical characteristics of hospital human influenza (influenza A (H1N1) pdm09, H3N2, and B) -related and hospitalized avian-origin influenza A (H7N9)-related viral pneumonia patients , find the different between them.\u003c/p\u003e\u003cp\u003eMethods: A retrospective study was conducted in hospitalized influenza-related viral pneumonia patients.\u003c/p\u003e\u003cp\u003eResults: Human influenza A -related patients in the 35–49-year-old group were more than those with B pneumonia patients (p=0.027), and relatively less in the ≥65-year-old group than B pneumonia patients (p=0.079). The proportion of comorbid condition to human influenza A pneumonia was lower than B pneumonia and H7N9 pneumonia patients (78% \u003cem\u003evs\u003c/em\u003e. 77.8%; p=0.013). The proportion of invasive mechanical ventilation (IMV), lymphocytopenia, elevated lactate dehydrogenase to hospitalized human influenza A-related viral pneumonia patients was higher than B pneumonia patients (p\u0026lt;0.05), but lower than H7N9 pneumonia patients (p\u0026lt;0.05). In the multivariate analysis, pulmonary consolidation (odds ratio (OR): 13.67; 95% confidence interval (CI): 1.54–121.12; p=0.019) and positive bacterial culture (sputum) (OR: 7.71; 95% CI: 2.48–24.03; p\u0026lt;0.001) were independently associated with IMV , while shock (OR: 13.16; 95% CI: 2.06–84.07; p=0.006), white blood cell count \u0026gt;10,000/mm\u003csup\u003e3\u003c/sup\u003e (OR: 7.22; 95% CI: 1.47–35.58; p=0.015) and positive bacterial culture(blood or sputum) (OR: 6.27; 95% CI: 1.36–28.85; p=0.018) were independently associated with death in the three types hospitalized influenza-related viral pneumonia patients\u003c/p\u003e\u003cp\u003eConclusions: Hospital influenza B-related viral pneumonia mainly affects the elderly and people with underlying diseases, while human influenza A pneumonia mainly affects the young adults; however, the mortality was similar. The hospitalized human influenza A-related viral pneumonia patients was severer than B pneumonia patients,but milder than H7N9 pneumonia patients. Pulmonary consolidation and positive bacterial culture (sputum) were independently associated with IMV, while shock, white blood cell count \u0026gt;10,000/mm\u003csup\u003e3\u003c/sup\u003e, and positive bacterial culture (blood or sputum) were independently associated with death to three types hospitalized influenza-related viral pneumonia patients.\u003c/p\u003e","manuscriptTitle":"A Comparison of Demographic, Epidemiological and Clinical Characteristics of Hospital Influenza-related Viral Pneumonia Patients","msid":"","msnumber":"","nonDraftVersions":[{"code":2,"date":"2020-09-11 13:53:35","doi":"10.21203/rs.2.24780/v2","editorialEvents":[{"type":"communityComments","content":0},{"type":"reviewerAgreed","content":"","date":"2021-04-11T00:00:00+00:00","index":1,"fulltext":""},{"type":"editorInvitedReview","content":"","date":"2021-04-11T00:00:00+00:00","index":1,"fulltext":"Recommendation: Reviewer's comments unavailable pending editorial decision\n"},{"type":"reviewersInvited","content":"","date":"2021-04-08T00:00:00+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2020-09-07T12:00:00+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2020-09-06T12:00:00+00:00","index":"","fulltext":""},{"type":"editorInvited","content":"","date":"2020-09-06T12:00:00+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"bmc-infectious-diseases","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"infd","sideBox":"Learn more about [BMC Infectious Diseases](http://bmcinfectdis.biomedcentral.com/)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/infd","title":"BMC Infectious Diseases","twitterHandle":"#bmcinfectdis","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"em","reportingPortfolio":"BMC Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true}},{"code":1,"date":"2020-02-27 22:41:49","doi":"10.21203/rs.2.24780/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Major revision","date":"2020-08-04T12:00:00+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2020-07-27T12:00:00+00:00","index":3,"fulltext":"Recommendation: Accept without revision\nForm responses:\n---\n\nComments to Author:\n---\nThank you for the manuscript and data comparisons regarding Influenza at the First Affiliated Hospital and Zhejiang University, China. The findings are very interesting and relevant, especially in the midst of the Covid-19 pandemic.* Publons Reviewer Recognition. Springer Nature can send verification of this review directly to Publons (a subsidiary of Clarivate Analytics). If you would like to take advantage of this service, please click on the “Yes” option below. Your name, email address, title of the reviewed manuscript, name of the journal, and date of your review submission (the “Review Data”) will then be transmitted to Publons upon publication of the manuscript. If you have already registered at Publons, they will notify you of the receipt of this review and update your profile as per your settings and their policy. If you are not registered with Publons, you will receive an email from them asking you to register in order for them to be able to recognize your review on your new profile page. Publons may use the Review Data to generate derivative metadata for the benefit of Publons and you as a reviewer, carefully considering the sensitivity of such information. For example, Publons may verify your record as a reviewer by updating your profile published on its webservice if you have registered for such service or help editors to identify candidate reviewers. Please find the details of processing in Publons’ privacy policy https://publons.com/about/terms: **Yes**\n* Declaration of competing interests: **I declare that I have no competing interests.**\n* Reviewer Publication Consent. I agree for my report to be made available under an Open Access Creative Commons CC-BY License (http://creativecommons.org/licenses/by/4.0) if this manuscript is accepted for publication. Any comments that I do not wish to be included in the published report have been included as confidential comments to the editor, which will not be published.: **I agree to the terms of the CC-BY 4.0 license; please do not publish my name with my report. (default)**\n* Is the study design appropriate to answer the research question (including the use of appropriate controls), and are the conclusions supported by the evidence presented?: **Yes**\n* Are the methods sufficiently described to allow the study to be repeated?: **Yes**\n* Is the use of statistics and treatment of uncertainties appropriate?: **Yes**\n* Is the presentation of the work clear?: **Yes**\n* Are the images in this manuscript (including electrophoretic gels and blots) free from apparent manipulation?: **Yes**\n"},{"type":"reviewerAgreed","content":"","date":"2020-07-03T12:00:00+00:00","index":3,"fulltext":""},{"type":"editorInvitedReview","content":"","date":"2020-06-28T12:00:00+00:00","index":2,"fulltext":"Recommendation: Accept after minor essential revisions\nForm responses:\n---\n\nComments to Author:\n---\nPlease include all comments for the authors in this box rather than uploading your report as an attachment. Please only upload as attachments annotated versions of manuscripts, graphs, supporting materials or other aspects of your report which cannot be included in a text format.\nPlease overwrite this text when adding your comments to the authors.\n The numbers are relatively small in some groups and this should be indicated.\nthe median age for all three groups are quite close to each other, and this should be noted.\nand the p values are marginal and this should be noted\n* Publons Reviewer Recognition. Springer Nature can send verification of this review directly to Publons (a subsidiary of Clarivate Analytics). If you would like to take advantage of this service, please click on the “Yes” option below. Your name, email address, title of the reviewed manuscript, name of the journal, and date of your review submission (the “Review Data”) will then be transmitted to Publons upon publication of the manuscript. If you have already registered at Publons, they will notify you of the receipt of this review and update your profile as per your settings and their policy. If you are not registered with Publons, you will receive an email from them asking you to register in order for them to be able to recognize your review on your new profile page. Publons may use the Review Data to generate derivative metadata for the benefit of Publons and you as a reviewer, carefully considering the sensitivity of such information. For example, Publons may verify your record as a reviewer by updating your profile published on its webservice if you have registered for such service or help editors to identify candidate reviewers. Please find the details of processing in Publons’ privacy policy https://publons.com/about/terms: **Yes**\n* Are the methods appropriate and well described?: **Yes**\n* Does the work include the necessary controls?: **Yes**\n* Are the conclusions drawn adequately supported by the data shown?: **Yes**\n* Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?: **I am able to assess the statistics**\n* Quality of written English: **Acceptable**\n* Declaration of competing interests: **i declare that i have no competing interests**\n* Reviewer Publication Consent. I agree for my report to be made available under an Open Access Creative Commons CC-BY License (http://creativecommons.org/licenses/by/4.0) if this manuscript is accepted for publication. Any comments that I do not wish to be included in the published report have been included as confidential comments to the editor, which will not be published.: **I agree to the terms of the CC-BY 4.0 license; please do not publish my name with my report. (default)**\n"},{"type":"reviewerAgreed","content":"","date":"2020-06-10T12:00:00+00:00","index":2,"fulltext":""},{"type":"editorInvitedReview","content":"","date":"2020-04-17T12:00:00+00:00","index":1,"fulltext":"Recommendation: Major revisions required\nForm responses:\n---\n\nComments to Author:\n---\nThank you for the opportunity to review the manuscript entitled \"A Comparison of Demographic, Epidemiological and Clinical Characteristics of Hospital Influenza-related Viral Pneumonia Patients\". This manuscript contains some interesting information about the clinical and demographic differences in patients with influenza A, influenza B and Influenza A H7N9\n\nGeneral comments: I find the manuscript interesting, but it has a lot of detail and that can detract from its main messages. The manuscript compares patients with seasonal influenza A and B with patients with novel influenza H7N9. There is so much discussion around the subtle differences of A vs B patients that the unique characteristics of the H7N9 patients gets a bit lost. It might be better to combine the seasonal A and B patients together and compare the seasonal influenza patients to the novel influenza patients, or leave out the H7N9 patients and compare the seasonal influenza patients to one another. Perhaps write two separate manuscripts 1) A vs B and 2) seasonal vs H7N9. \n\nSpecific Comments:\nMethods/Results:\nSince this is a retrospective study and the authors used data from the electronic medical record for the study, can the authors please comment in the methods or the results about the completeness of the data set.\nCould the authors please go into a little more detail about how the diagnosis of pneumonia was made. This is not so clear given that this is a retrospective study.\nTables\nCombine Seasonal influenza and compare to H7N9. The three-way comparisons (last column) are a little difficult to digest.\nDiscussion\nThere are some very interesting and valuable sections to the discussion, but the discussion should be more focused.* Are the methods appropriate and well described?: **Yes**\n* Does the work include the necessary controls?: **Yes**\n* Are the conclusions drawn adequately supported by the data shown?: **Yes**\n* Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?: **I am able to assess the statistics**\n* Quality of written English: **Needs some language corrections before being published**\n* Declaration of competing interests: **I declare that I have no competing interests.**\n* I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.: **\nI agree to the open peer review policy of the journal**\n"},{"type":"reviewerAgreed","content":"","date":"2020-04-07T12:00:00+00:00","index":1,"fulltext":""},{"type":"editorAssigned","content":"","date":"2020-02-26T12:00:00+00:00","index":"","fulltext":""},{"type":"reviewersInvited","content":"","date":"2020-02-26T12:00:00+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2020-02-25T12:00:00+00:00","index":"","fulltext":""},{"type":"editorInvited","content":"","date":"2020-02-25T12:00:00+00:00","index":"","fulltext":""},{"type":"submitted","content":"","date":"2020-02-23T12:00:00+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"bmc-infectious-diseases","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"infd","sideBox":"Learn more about [BMC Infectious Diseases](http://bmcinfectdis.biomedcentral.com/)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/infd","title":"BMC Infectious Diseases","twitterHandle":"#bmcinfectdis","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"em","reportingPortfolio":"BMC Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"c7601781-fb21-4baa-b9f7-3e2dc013512a","owner":[],"postedDate":"September 11th, 2020","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"under-review","subjectAreas":[{"id":63507,"name":"Infectious Diseases"}],"tags":[],"updatedAt":"2020-09-08T13:54:47+00:00","versionOfRecord":[],"versionCreatedAt":"2020-09-11 13:53:35","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v2","identity":"rs-15338","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"identity":"rs-15338","version":["v2"]},"buildId":"FbvkV6FR0MCFSLy54lSbu","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}